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The glyoxalase pathway is widespread in both prokaryotic and eukaryotic 
organisms. This system utilizes two enzymes (glyoxalase I (GlxI) and glyoxalase II 
(GlxII)) to catalyze the formation of D-lactate from the substrates glutathione (GSH) and 
methylglyoxal (MG). The latter chemical is a harmful byproduct of glycolysis. This 
thesis gives detailed studies of the behavior of the GlxI enzyme as it pertains to its thiol 
co-substrate specificity, its structural similarity among its superfamily members (most 
particularly with the fosfomycin resistance protein (FosA)) and residue identification that 
would alter its metal selectivity. 
The thiol co-substrate GSH was thought to be the only thiol utilizied by the 
glyoxalase system. However, reports identified organisms that utilized the thiols 
trypanothione (T(SH)2) and glutahionylspermidine (GspdSH) as co-substrates. These 
organisms, known as the trypanosomes, are very well known in tropical environments to 
cause diseases. E. coli does not contain T(SH)2 but does contain GspdSH and 
manufactures the latter in increasing amounts under conditions of cell duress. Substrate 
specificity studies were conducted replacing GSH with GspdSH and T(SH)2. In addition 
to this, to ensure the thiols reacted in a true glyoxalase system, substrate specificity 
studies were also conducted on the second enzyme GlxII and verification of the product 
D-lactate was performed. 
To continue, structurally, the enzyme GlxI belongs to the βαβββ superfamily of 
proteins that are known to have very similar structure but to catalyze very different 
reactions. Comparing the active site of E. coli GlxI and FosA, there is one significant 
difference at one residue. Therefore an E56A mutation was performed on GlxI and the 
 iv 
mutant bacterium were subjected to growth analysis in the presence of fosfomycin and 
MG. The mutant enzyme was also tested for its performance in the presence of MG and 
various divalent metals. 
Further, the Glx I enzyme from E. coli is known to be active in the presence of 
non-zinc bivalent metals, while the human counterpart is active in the presence of Zn2+. 
When one compares GlxI from E. coli with the human GlxI, there are many differences in 
the primary structure that could be viable areas that determine the metal specificity of the 
enzyme. Mutation analysis was performed on these areas to determine catalytic 
performance as well as metal specificity. 
These studies display how versatile the glyoxalase system is with regard to the 
use of its thiol co-substrates. These thiols participate in the detoxification pathway for 
MG in the cell especially under late log phase conditions. Structural studies can give 
some knowledge concerning the possible evolution of the enzyme among its family 
members, and is of monumental significance to the scientific community as it relates to 
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CHAPTER 1: I!TRODUCTIO! TO THE GLYOXALASE 
SYSTEM 
THE GLYOXALASE SYSTEM 
 
The ubiquitous glyoxalase system (1) is now considered to be a critical 
detoxification route present in the cytosol of cells. First identified in 1913 (2), it was 
thought to be involved in glycolysis. The system uses the tripeptide thiol cofactor 
glutathione (GSH; γGlu-Cys-Gly) to eliminate α-oxoaldehydes and cytotoxic compounds 
(2, 3).  
In order to perform this task, two enzymes are recruited for the system. The first 
enzyme glyoxalase I (GlxI) (S-lactoylglutathione lyase, EC 4.4.1.5), which converts the 
hemithioacetal formed non-enzymatically from GSH and methylglyoxal (MG) into S-
lactoylglutathione (3). This reaction is stereospecific, forming the diastereomer S-D-
lactoylglutathione (4). The thioester produced in this reaction is then hydrolysed to D-
lactate by the second enzyme in the system glyoxalase II (GlxII) (hydroxyacylglutathione 
hydrolase, EC 3.1.2.6).  
It is now known that the glyoxalase system is a major detoxification pathway of 
MG (5). Studies in Escherichia coli where null mutant GlxI, GlxII and glyoxalase III 
(GlxIII) cells were grown against wild type enzymes showed an increase in viability of 
the wild type over expressed GlxI enzymes versus the null mutant and no significant 
change occurred with mutations in GlxII and GlxIII. The authors also concluded that the 
GlxI enzyme is therefore the most catalytically competent against MG rather than the 




























































In the 1930s, methylglyoxal (MG, 2-oxopropanal) was thought to be a key 
intermediate in the breakdown of glucose in animals, plants, and microorganisms due to 
studies showing its production from cell free extracts (6, 7). Initially, the appearance of 
MG was thought to be as a result of the acid-catalyzed breakdown of accumulated 
triosephosphates and this view was widely held for some twenty years (8). Much is 
known since then about the mechanism of formation of MG, and its cytotoxic nature in 
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the cells (9-13). MG has been detected from numerous sources and produced in the cells 
in cytotoxic concentrations (10).  
PRODUCTIO! OF MG 
 
Many routes of MG production exist in higher organisms, but they are poorly 
documented in microorganisms (11). Extensive studies have indicated that MG may be 
produced both enzymatically and non-enzymatically (3, 10). In 1952 MG accumulation 
was detected during glucose catabolism by iodoacetate-poisoned cells of Pseudomonas 
saccharphilla (14). Under these conditions, it was thought that MG was made from 
glyceraldehyde-3-phosphate, and one mole of glucose was converted to one mole of 
pyruvate and one mole of MG (10). Even though there are many ways of production, it 
wasn’t until 1964 that Wang et al. started to clarify the mechanism by which MG is 
produced in cells. MG production was detected in E. coli during glucose catabolism (15). 
This further strengthened the first hypothesis and as a result scientists performed studies 
on E. coli mutants lacking triosephosphate isomerase (TIM) (EC 5.3.1.1). Results showed 
that glyceraldehydes could not be obtained in the presence of glycerol even though the 
strains produced dihydroxyacetone phosphate (DHAP). Further study on the cell free 
extracts from the mutant strains indicated that MG could be formed from DHAP and not 
glyceraldehydes (11, 16). In addition to this, a MGsynthase (MGS, EC 4.2.99.11) was 
found and it is believed to also serve as a source of MG (17). 
Experiments in E. coli cells, where MGS was overexpressed about 1000-fold, 
displayed undetectable amounts of MG accumulation indicating that the rate at which 
MG is detoxified exceeds the rate at which it is produced (18). At present it is thought 
that the primary role of MGS is its function in relation to the glycolytic bypass. Here 
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MGS serves to relieve the inhibition that would have occurred if sugar phosphates were 
allowed to accumulate in the cell (18). Studies dealing with E. coli in phosphate-limited 
growth media lead to slight accumulation of MG that could be stimulated with the 
overexpression of MGS. This appears to signify that optimal MG production conditions 
require low phosphate and high DHAP and that MG production can be stimulated by 
increasing the carbon source available to the bacteria (5, 16). 
MECHA!ISM OF MG FORMATIO! 
 
MGS catalyses the conversion of DHAP to MG and inorganic orthophosphate 
(16). It has also been shown that MG may be formed from the TIM-catalyzed reaction 
(displayed in Scheme 2.) (19) as well as from MGS reactions.  Researchers Summers et 
al. have determined that the mechanisms of action of both enzymes are similar in that 
MGS and TIM both utilize DHAP in the initial reaction pathway forming the phospho-
enediolate intermediate. In the case of MGS reaction path b is taken supporting oxidation 
of the hydroxymethyl group of the DHAP to yield an aldehyde group, while the C1 
carbon undergoes dephosphorylation and reduction leading to the collapse of the 
enediolate to form MG (20).  
 In the case of the TIM reaction there is reprotonation forming the isomer of 
DHAP which is D-glyceraldehyde-3-phosphate (DGAP) (21). Under these conditions, 
uninhibited buildup of MG may be as much as 0.4 mM per cell per day even though only 
about 1 in 100,000 turnovers of TIM produces MG (3, 22). DHAP is first converted to 












































Scheme 2. Enzymatic formation of MG from DHAP to DGAP where MG is formed from the 
elimination of inorganic phosphate (19).  
 
MGS A!D TIM E!ZYMES 
 
The first scientists to purify MGS, observed a homotetramer of 16.9 kDa 
subunits (16). Their studies indicated that the enzyme was homotropically activated by 
the substrate, and allosterically inhibited by the phosphate product (16). These 
researchers Saadat et al. predicted that there would be some similarity in the crystal 
structures of MGS and TIM (both displayed in Figure 1). The structure of MGS from E. 
coli has been determined (21) and found to be a homohexamer having an interacting five-
stranded beta/alpha structural arrangement, where as the TIM enzyme has an alpha/beta 
barrel structural array (23). There are some conserved residues: His-19, Asp-71, and His-
98 in each of the three monomers in the asymmetric unit. Differences in the three 
monomers in the asymmetric unit are localized at the mouth of the active site and this 
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Figure 1. Crystal structure representations of MGS (PDB code: 1B93) (A) (21) and TIM (PDB code: 
2TRE) (B) (23) from E coli..  
 
OTHER ROUTES OF MG PRODUCTIO! 
 
It may also be important to note that the MG pathway has been suggested as a 
bypass of the Embden-Meyerhof pathway (10). This has been reported since the 1930s 
showing that organisms that do possess glyoxalase activity also posses flavin-linked D-
lactate and L-lactate dehydrogenases (EC 1.1.2.4; EC 1.1.2.3 respectfully) that form 
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pyruvate from lactate under aerobic conditions (24). Therefore as MG is produced it is 
transformed to D- or L-lactate and then converted into pyruvate.  
 
Figure 2. Truncated representation of the Embden-Meyerhof pathway showing the MG bypass (10). 
 
CYTOTOXIC !ATURE OF MG 
 
Recent in vivo analysis of gene expression suggests that MG holds a key role in 
the physiology of intracellular pathogens (25). In the bacteria Salmonella and Brucella, 
studies indicated that when these organisms were engulphed by macrophages, the 
bacteria seemed to express high levels of GlxI (25, 26).  
Initial reports of MG cytotoxicity have appeared with regard to its effect on 
protein synthesis (27). Evidence indicates that the mechanism of cell growth inhibition 
may be distinct from loss of cellular viability (24). It is now understood that MG acts as 
an electrophile that may be attacked by nucleophilic centers of macromolecules in the cell 
(5). When MG reacts with cysteine residues, it could be significant enough to cause 
growth retardation (28). It is now known that MG negatively affects numerous processes 
such as DNA and RNA biosynthesis (29). In addition to this, MG affects protein 
Glucose 
Dihydroxyacetone phosphate Glyceraldehyde-3-phosphate 
MG 
D-lactate or L-lactate 
Pyruvate 
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synthesis as it relates to DNA elongation. The method of action of MG on protein 
synthesis has been suggested through studies of its interactions with the ribosome (30, 
31). The mechanisms of these reactions have remained unclear (30). However, studies 
show that MG also reacts rapidly with 7-methylguanosine (32), which is present in both 
16S and 23S RNA (33). Even though this is the case, the effect seen on macromolecular 
systems may be due to general damage rather than reactions of MG on specific enzymes 
or complexes (34). To continue, MG reacts non-specifically with thiol groups of proteins 
causing inhibition which could result in the inactivation of many enzymes in the cell (28). 
 MG has been documented as a known mutagen, this implies that the DNA 
damage may occur as a result of its interaction with MG. This damage will not only be 
present in the cell; but, the damage possibly transcends to surviving cells in the progeny 
(35, 36). Experiments in this regard in  E. coli, have shown that fragmentation of the 
progeny genome occurred when the parental E. coli cells were treated with MG (37). 
Further, a correlation has been found between the effectiveness of MG 
degradation in cells with cell density and MG concentration. In E. coli for example, a 
0.25 mM concentration of MG inhibited cellular growth in media containing 3 x 108 cells 
mL-1, while concentrations of 0.1 mM MG inhibited cellular growth in media containing 
3 x 106 cells mL-1 (30). The variation of MG needed to inhibit growth depends inherently 
on the cells ability to detoxify MG which underlies the efficiency of the glyoxalase 
system (10). 
DEGRADATIO! OF MG 
 
The cell has developed very interesting routes of MG degradation by converting 
MG to other useful adducts such as rapidly forming GSH adducts with the oxoaldehyde 
 9 
in the cytoplasm. The isomerization of the MG –GSH adduct followed by its hydrolysis 
in the cell would then lead to the formation of pyruvate (38, 39).  
Simultaneously, MG can also react with guanine bases present in DNA, to form 
3
2-(1-carboxyethyl)-9-methylguanine, which in turn has been shown to become the 
substrate for DNA repair enzymes (40).  
MAJOR E!ZYMATIC ROUTES OF MG DEGRADATIO!  
 
One most important route of the detoxification of MG is the aforementioned 
glyoxalase pathway (3).  It is pertinent to note that since MG contains two functional 
groups it may either be oxidized or reduced. The other main pathway that has been 
discovered is through MG’s reaction with the enzyme MG dehydrogenase (MGD, EC 
1.2.1.23) which oxidizes MG to pyruvate. This was first identified when pyruvate was 
formed in a Pseudomonad after the organism was grown on aminoacetone (41). 
Interestingly, it seems that in organisms that possess high glyoxalase activity the purified 
MGD appears to have a low turnover rate. However the opposite occurs in certain Gram-
positive organisms that possess low or undetectable levels of glyoxalase activity grown 
on acetone or isopropanol; here, MGD has high activity (10).  
OTHER E!ZYMATIC ROUTES OF MG DEGRADATIO! 
 
Due to MG’s bifunctional nature as it relates to its redox capabilities, many 
enzymes in the cell can actually utilize MG as a substrate. MG can be degraded by the 
enzyme α-oxoaldehyde dehydrogenase (2-oxoaldehyde:NAD(P)+ oxido-reductase (EC. 
1.2.1.23)) which uses both NADP+ and NAD+ as cofactors (42, 43). 
When MG is reduced, acetol or lactaldehyde are expected products (44). Some 
oxido-reductases and dehydrogenases that are present in the cytosol, and that have broad 
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substrate specificity, are able to accept MG as a substrate. Such enzymes are aldehyde 
reductase (alchohol:NADP+ oxido-reductase, EC. 1.1.1.2) (45), aldose reductase 
(alditol:NADP+ oxido-reductase, EC.1.1.1.21) (46) and carbonyl reductase (EC. 
1.1.1.184) (47). All these enzymes possess a NADP+ requirement (44). 
 It has been shown that reduction of MG by aldose reductase produces 
approximately 95% acetol and about 5% D-lactaldehyde (47) but this is very noteworthy 
as in the cell L-lactaldehyde is the usual product (44). Inspecting the family of aldehyde 
dehydrogenases (EC.1.2.1.3) more closely this family consists of three isoenzymes that 
differ with intracellular location and are reported to all utilize MG as a substrate (48). 
One particular oxido-reductase has been discovered and termed GlxIII. This 
novel enzyme seems to bypass the two enzyme system process by converting MG into D-
lactate directly in the absence of GSH (49). The enzyme is not activated nor inhibited by 
the presence of GSH. GlxIII was first purified and characterized from E. coli and found to 








Figure 3. MG Routes of Degradation (3, 10, 36, 43-49). 
 
GLYOXALASE I (GLXI) 
 
The glyoxalase system has been thus far studied in humans, higher plant system 
and microorganisms. In these studies GlxI has been shown to be more active in the 
presence of an increased carbon source (50), related to increased DNA synthesis (51), and 
is critical for life support as it is active in embryogenesis, tissue maturation and even 
persists until cell death (52). 
OVERALL STRUCTURE OF GLXI 
 
GlxI has been classified as a member of the βαβββ superfamily of proteins (53). 












































Figure 4. Structural topology of the βαβββ superfamily of metalloproteins showing anti-parallel β 
strands separated by an α-helix between the β1 and β2 positions (53). 
 
 Members of this family can be categorized by their overall structure, but may 
differ drastically from each other in function (54). Protein members such as the 
bleomycin resistance protein (BRP, EC 3.4.22.40 ) from Streptoalloteichus hindustanus 
(55), 2,3-dihydroxy-biphenyl 1,2-dioxygenase (DHBD) from Burkholderia cepacia (56) 
as well as the human enzyme (GLO) (57) have the conserved βαβββ topology associated 
with the superfamily even though these enzymes when compared have very low sequence 
homology, less than twenty percent as well as significant differences in their monomer 
sizes and oligomeric states and functions (53). In spite of this, the overall structures of the 
proteins are very similar (53). 
In terms of metal activation, the active sites of BRP, DHBD, and GLO activated 
two bleomycin molecules, a non-heme Fe 2+ or Mn 2+, and a Zn 2+ ion respectfully (53).  
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Figure 5. Structural comparison showing the overall topology of the βαβββ superfamily of proteins: 
homodimer of Bleomycin resistance protein (BRP) (PDB code: 1qto) (55), monomer of 2,3-
dihydroxy-biphenyl 1,2-dioxygenase (DHBP) (PDB code: 1eil) (56), homodimer of human glyoxalase 
I (GlxI) (PDB code: 1fro) (57) and homodimer of methylmalonyl-CoA epimerase (MMCE) (PDB 
code: 1jc5) (58). 
 
Furthermore, it is thought that the families of proteins that are derived from 
gene duplication, tend to have very closely related functions as their primary functions 
tend not to diverge beyond certain stages (53, 54). In the case of methylmalonlyl-CoA 
epimerase (MMCE) (58), which is a member of the βαβββ superfamily the enzyme 
functions very similarly to GlxI. Like GlxI it catalyzes the isomerization reaction 
involving an enediolate intermediate (58). In addition to this, there are four metal ligands 
associated with both enzymes. In human GlxI the metal ligands are located at : His-12, 
Gln-65, His-91, and Gln-141 (58). Now, due to the similarities among these enzymes in 
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structure and catalytic activity, it has been implied that the members of the βαβββ 
superfamily exist due to divergent evolution from one common ancestor, where a series 
of events such as gene duplication, gene fusion and accumulation of gene point mutations 
followed (these details will be discussed later) (53). 
A general trend in the molecular properties of GlxI may be seen in the following 
table. Molecular masses range from approximately 20-48 kDa. GlxI is a metalloenzyme 
which falls into classes: Zn 2+ and non-Zn 2+ activated. It is now evident that GlxI 
contains no activity in its apo form. Generally, the Zn 2+ enzymes are present in 
mammalian systems, where each subunit contains one Zn 2+ ion. The microbial enzymes 
have shown some activity with other bivalent metal ions such as: Mn 2+, Co 2+, Ni 2+ but 
not with Zn 2+ (57, 59-62). 
Table 1. Properties of GlxI enzymes found in some microbial and mammalian systems (63).  
 








    
Eukaryotes    
Human erythrocyte 46 2 4.8 
Pig erythrocyte 48 2 4.8 
Rat liver 46 2 4.7 
Sheep liver 46 2 5.0 
Yeast (Saccharomyces cerevisiae) 32 1 7.0 
 
Prokaryotes    
E. coli 14 2 4.5 
Pseudomonas putida 20 1 or 2 4.0 





STRUCTURE OF HUMA! GLYOXALASE I 
  
The structure of GlxI enzymes from Homo sapiens and E. coli have been well 
characterized (57, 64). In humans, GlxI is a 43 kDa homodimer (57). The translation 
product of the human glxI gene contains 184 amino acids. The monomers of the protein 
exhibit the βαβββ topology joined by a 20 amino acid linker (57), with the active site 
lying at the dimer interface of the protein. H. sapiens GlxI was isolated with a Zn 2+ 
complex with a stoichiometry of one zinc ion per subunit of enzyme.  
In this case, if the first subunit is coined a and the second b, Zn 2+ is coordinated 
by side chains from both subunits: Gln-33a, Glu-99a, His-126b, Glu-172b and two water 
molecules in an octahedral coordination. Of interest, there exsists the presence of a long 

































































































































































STRUCTURE OF E. COLI GLYOXALASE I  
 
The structure of E. coli GlxI has been determined. The gene translation product 
produces an  enzyme consisting of 135 amino acids (65). This enzyme is homodimeric 
and each subunit displays βαβββ motifs, linked by a 12 amino acid spacer. Both this 
bacterial and the aforementioned human enzyme have much similarity in structural 
topology except for the absence of the 29 amino acid N-terminal arm present in the 
human enzyme that wraps around the adjacent subunits (64).  
When comparing the E. coli and human enzyme, there is a deletion of 15 amino 
acids in the bacterial enzyme corresponding to an α-helical loop that lies in the active site 
of the human enzyme. This may have a direct effect on the active site, as it is larger in the 
E. coli enzyme than in the human counterpart and displays an octahedral metal 
coordination. However, the E. coli GlxI has been inactivated in the presence of Zn 2+ but 
optimally active in the presence of Ni 2+. Ni 2+ is also retained in the native protein when 
purified and is coordinated by His-5 and Glu-56 from one monomer and His-74 and Glu-







   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   






















































































































































MECHA!ISM OF ACTIO! OF GLYOXALASE I 
 
The physiological cofactor of GlxI is the tripeptide GSH, and GlxI from a range 
of sources such as plants, yeast, mammals and many bacteria utilize this cofactor. GlxI 
enzymes from these groups display a wide range of substrate utilization. The molecular 
species that actually acts as the substrate for GlxI is the hemithioacetal, formed non-
enzymatically from α-oxoaldehydes (MG is most predominant) and GSH.   
The suggested enzyme mechanism of GlxI has been modified over the years 
(57). Primarily, the reaction was thought to occur by means of an internal hydride 
transfer, due to the lack of isotope washout in the product when the reaction is permitted 
to take place in deuterated or tritiated water (66). Later, NMR experiments were 
successful in detecting deuterium incorporation into the product with the solvent washout 
proving to be temperature dependent. The latter findings suggested an enediol-proton-
transfer mechanism that is partially shielded from solvent. Further supporting this 
hypothesis, the production of a fluoride ion from the turnover of fluoromethylglyoxal to 
give pyruvylglutathione was detected under GSH-dependent catalysis by GlxI. These 



































Scheme 3. Proposed overall mechanism of GlxI (61). 
 
GLXI E!ZYME MECHA!ISM I! H. SAPIES 
 
The enzyme mechanism of GlxI (displayed in Scheme 3..) has been extensively 
studied for the human enzyme and is believed to occur via a proton abstraction by Glu-
172 (EnzB-) based on its proximity 2.33 Å to the modeled substrate when the structure of 
an inhibitor-enzyme complex was analyzed (65). Glu-172 is observed to have completely 
dissociated from the Zn 2+ ion in the presence of a transition state analog. Proton 
abstraction is then believed to result in the electron redistribution of the substrate forming 
the proposed cis-enediolate intermediate. Here, the charges on oxygen may permit strong 
bonding to the metal ion and Glu-99 consequently serves as a possible means for 
hydrogen bonding to the hydroxyl group of the intermediate which is only now slightly 
coordinated to the metal ion (65). Re-protonation on C-2 produces the product S-D-
lactoylglutathione (65). 
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The mechanism for release of the substrate as well as the function of water 
molecules in the active site is still unclear; there are two possibilities for the production of 
S-D-lactoylglutathione from the enzyme (19, 59). The first maybe due to a direct proton 
transfer of H-2 to O-2 via Glu-99. Both of the substrate’s oxygen atoms would be weakly 
coordinated to the metal and the glutamate residues would be strongly bonded to the 
metal, resulting in substrate release and the end of the catalytic cycle (59). In the second 
scenario, both oxygen atoms could be weakly coordinated to the Zn 2+ ion but hydrogen 
bonded to the Glu-99 and Glu-33 residues. Nearby water molecules might then protonate 
the oxygen atom which is hydrogen bonded to Glu-33 (59). However, possible problems 
arise in the latter mechanism as the water molecule must be activated and there is no 
































































































































































































































































































































































































MECHA!ISM OF ACTIO! I! E. COLI 
 
The catalytic mechanism for E. coli GlxI has not been as extensively 
investigated as for its human counterpart. There are homologous amino acid sequences 
and similar three dimensional structures, but they differ in their metal ligands (59, 64, 
65). In a recent publication, it is proposed that the Glu-122 will act as a catalytic base 
(61). It has also been proposed that the metal specificity of GlxI may depend on the 
enzyme’s structure, allowing for the E. coli GlxI enzyme to be maximally active in the 
presence of Ni 2+ and not Zn 2+ (61). This may affect the mechanism, as the active site is 
more accessible to solvent due to the absence of regions of the protein that are present in 
the human enzyme. It is therefore proposed that the E. coli enzyme’s water molecules act 
as substrate polarizers that serve in proton extraction (61, 64).  
STEREOSELECTIVITY OF GLXI 
 
Stereochemical studies gave support early on for a cis-enediolate mechanism, 
where GlxI reacted with either stereoisomer producing instead of an R configuration, 














Scheme 5. GlxI reaction with both enantiomers of lactoylglutathione producing only the S-
lactoylglutathione (4). 
 
Since there is high symmetry between Glu-172 and Glu-99 at the active site it suggests 
symmetric mechanisms for the S and R mechanisms. Individual reaction steps are 
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identical with the most important difference being that in the S reactions, Glu-172 would 
perform all proton transfer steps. Glu-99 could not perform this step without producing 
the wrong enantiomeric product.  Therefore it is logical to assume that Glu-172 in the R 
mechanism is involved in the transfer of the second proton (67).  
GLYOXALASE II 
 
Glyoxalase II (GlxII) is the second enzyme in the two part glyoxalase system. 
GlxII hydrolyses the thioester to produce GSH and free 2-hydroxycarboxylic acid. The 
importance of the glyoxalase system have been outlined previously, however one report 
indicated the importance of GlxII in spermatogenesis (68). 
STRUCTURE OF HUMA! GLYOXALASE II 
 
The crystal structure of human GlxII indicates that it is a 29 kDa monomer and 
this enzyme has no sequence similarity to GlxI (69). Overall the enzyme consists of two 
symmetrical domains. This was first postulated from data obtained via limited-proteolysis 
studies (70). 
The 3-terminal domain contains 173 amino acids and the enzyme has a four-
layered β sandwich topology with two mixed β sheets flanked by α helices. In the first 
half of the sandwich, there is a βββαβαββ topology and the second half folds in the 
manner of ββββαβ. This domain is structurally similar to the whole structure of the 
metallo-β-lactamases. When comparing GlxII with its family of enzymes, the 3-terminal 




Figure 8. Overall topology of GlxII. The approximate two fold axis shown located between the two 
sets of β-sheets (69). 
 
The C-terminal domain consists of residues 174-260 which is folded into five 
alpha helices (69). This again was first suggested from circular dichroism experiments 
when Aceto et al. hypothesized that the C-terminal domain may consist of predominantly 
α helices (70). The two domains interact very tightly, a hairpin loop located in the 3 
terminal domain protrudes into the C-terminal domain and makes both hydrophobic and 




Figure 9. Structure of GlxII with labeled secondary structure and active site (AS) shown. (PDB code: 
1qh5) (69). 
Analyzing the active site more closely, there is a clear electron density in the 
active site giving evidence of a binuclear metal center present in the human GlxII 
enzyme. According to metal analysis there are approximately 1.5 moles of Zn2+ per mole 




























seven protein residues and one water molecule interact directly with the two zinc ions. 
Studies indicate that the metal ions are separated by a distance of 3.3-3.5 Å and are 
bridged by both a water molecule and Asp-134 (69). 
Complexing the enzyme with cacodylate in the active site, showed the 
coordination sphere of each metal. Both Zn1 and Zn2 are coordinated by two oxygen 
atoms showing an octahedral coordination. Now, when GSH was present in the active 
site an oxygen molecule is about 2.5Å from Zn1 and the sulphur of the GSH is 2.8Å from 
Zn2 and both are in similar positions as present in the cacodylate ion (69). 
The authors then concluded that coordination is octahedral. Although it is more 
common to have Zn2+ as tetrahedral structures in proteins (72), there are proteins where 
this is not the case (73) such as leucine aminopeptidase (74), and purple acid phosphatase 
(75) which contain octahedrally coordinated Zn2+ as part of a binuclear metal cluster. In 
the case of GlxII the Zn2+ ions are stabilized by either direct or indirect interactions with 
other residues (69). 
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Figure 10. Structure of GlxII active site showing zinc ions (blue) and a bridging water molecule (red) 
(69). 
It seems that the metal site in GlxII coincides with the metal binding sites of the 
other proteins in the metallo-β-lactamases located at one edge of the β sandwich , with 
the active site extending from its metal-binding site across the domain interface (69). 
However in this family, the metal binding site across its members is very similar but not 
necessarily conserved. So far only a few structures of this family have been elucidated 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MECHA!ISM OF ACTIO! OF GLXII 
 
GlxII is a very efficient enzyme as the kcat/Km is close to the diffusion limit when the 
natural substrate S-D-lactoylglutathione is present (78); and the the human liver enzyme  for 
example, possesses optimal activity in the pH range of 6.8-7.5 (79).  
Analysis of the x-ray structure that was complexed with the poorer substrate S-
hydroxybromophenylcarbomyl glutathione (HBPC-GSH) provided detailed information about 
the nucleophilic attack on the substrate. There is a water molecule coordinated to the two zinc 
ions situated below the plane of the carbonyl bond of the HBPC-GSH that is 2.9 Å from the C1 
carbon which is regiochemically ideal for attack. The true substrate for the reaction would be a 
little different in terms of the coordination in the active site (79) but it seems likely that the water 
molecule is the nucleophile. It is possible that this interaction will lower the pKa of the water 
molecule significantly for it to exist as a hydroxide and then there would be no need for a base 
catalyzed abstraction of the proton. This same water molecule is also in the vicinity of the Asp-
58. There is no evidence supporting Asp-58 playing a role in the proton transfer but it might be 
important to orient the hydroxide for the attack and modifies the pKa (69). 
When analyzing the active site of the enzymes of the metallo-hydrolases a nucleophilic 
attack would result in a tetrahedral intermediate that is negatively charged.  However, no 
residues are in the vicinity to support stabilization of the oxyanion. There is a Tyr-145 that is 
4.1Å from the oxygen atom whose hydroxyl may be able to be involved but it is not conserved 
among the GlxII enzymes and is also not in a very good position for hydrogen bonding. This 
carbonyl oxygen of the substrate (as shown in scheme 6) is only 3.1 Å from the Zn1. There is 
evidence to support this type of coordination. In the leucine aminopeptidases which are binuclear 
zinc enzyme, a hydroxide may be shared between two zinc ions that do attack the substrate to 
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form the intermediate in which the oxygen atoms are coordinated to the zinc ion (75). There is no 
evidence that this occurs in GlxII but it is possible to model a putative structure where the 
transition-state molecule is stabilized by both oxygen atoms interacting closely with Zn1 that 
provides the nessessary stabilization of the negative charge (69).  
For the reaction to be complete the release of the product by breaking the C1-S bond 
must take place and the intermediate in the active site needs to be replaced by water molecules. 
Thus far there is not enough information for an accurate determination of this process. However, 
experiments indicate that Zn2 is close to the sulfur atoms of HBPC-GSH (3.3Å) and GSH (2.9Å); 
therefore, the zinc ion could stabilize a thiolate ion formed with the bond breakage (69). The 
hydroxyl oxygen of Tyr-175 is located about 3.6Å from the sulphur postulating its role in the 
mechanism (69); however, this could be incorrect, as chemical modification studies suggest that 
























































Scheme 6. Proposed reaction mechanism in the GlxII active site (69). 
Reaction scheme 6 also supports the mechanism proposed for the binuclear metallo-β-
lactamases as it is involved in amide bond hydrolysis of the β-lactams (69). In this mechanism 
there is a nucleophilic attack of the shared hydroxide on the carbonyl carbon of the β-lactam (81, 
82). The aspartic acid (Asp-58) found in this vicinity as it is related to GlxII is conserved in the 
metallo-β-lactamases (82). Crystal structures of these organisms have not been solved, however 
modeling studies indicate that the Zn1 and Zn2 interact with the carbonyl oxygen and nitrogen of 
the β-lactam respectively (81, 82). This is very promising in determining the mechanism of GlxII 
as the situation mentioned is mimicked by the nitrogen replacing the sulphur atom of the 




CHAPTER 2: FU!CTIO!S OF I!TRACELLULAR THIOLS 
THIOL CO-SUBSTRATE GLUTATHIO!E  
 
Glutathione (GSH; γ-glutamylcysteinylglycine) was first discovered in 1888 from 
ethanol extracts of bakers yeast and the molecular formula was established in 1921 (83, 84). This 
molecule is a tripeptide of glutamate, cysteine and glycine and contains a γ-peptide bond 
between the glutamate and cysteine. This bond prevents the GSH from being hydrolyzed by 
many peptidases and is not easily oxidized than both cysteine and γ-glutamylcysteine (85).  
GSH is known as the most prominent non-protein thiol present in eukaryotes and many 
prokaryotic organisms (85, 86) and is the most abundant intracellular thiol, with concentrations 
ranging from 0.2-10 mM in these cells (85). GSH has been found to be the major non-protein 
thiol bound to several proteins under basal conditions (87-90).  
GLUTATHIO!E FU!CTIO! A!D METABOLISM 
 
GSH is involved in many physiological processes and is used by many enzymes. For 
example the GSH S-transferase family of enzymes can react non-enzymatically with toxic 
compounds to form GSH conjugates (85).  There are also several cellular roles for this thiol 
including its contribution as a redox cofactor and reductant. In its reduced form, GSH acts as an 
antioxidant against reactive oxygen species (ROS) by preventing oxidation of cellular thiols; it 
removes lipid peroxides and hydrogen peroxide via reactions catalyzed by glutathione 
peroxidases (85).  
In addition to this, thiol transfer reactions also allow for GSH’s assistance in protein 
folding (91). Most of the reactions that involve GSH depend upon the thiol group that 
participates in both one and two electron reactions. In one electron reactions, thiyl radicals form 
due to electron abstractions by biological free radicals. These thiyl radicals then recombine to 
  
 34 
form the oxidized glutathione disulfide (GSSG) which possesses a stable disulfide. As a result, 
GSH acts as the final electron sink for various radical reactions that would otherwise have 
undergone autocatalytic propagation. If left unchecked, this would result in widespread tissue 
injury and cell death (91). GSH also participates as a coenzyme in amino acid transport, in the 
maintenance of thiol moieties of proteins and low molecular weight compounds such as cysteine 
and coenzyme A. 
 
























GLUTATHIO!E REDUCTASE (GR) 
 
GSH functions in the cell in order to keep redox homeostasis as previously stated. In 
order to perform this function, it must be oxidized. However, in the cell there is a high ratio (30-
100) of GSH to GSSG (92). This intracellular regeneration is achieved by the reduction of 
oxidized GSH by glutathione reductase (GR, EC. 1.8.1.7) (85). 
STRUCTURE OF GR 
 
The crystal structure of GR has been solved for the human and the E. coli enzymes 
(92). GR is a homodimer for both sources where both of the subunits participate in catalysis. The 
E. coli GR is a 49 kDa protein containing 420 amino acids (92).The substrate GSSG is bound 
between the subunits and is processed by side chains extending from both subunits, in the human 
enzyme for example, these are Cys-58, and His-467 (93). From crystal structure analysis, the 
interface area can be divided into an upper and a lower part. They are separated by a cavity with 
channel extensions to the solvent. The upper part is termed the interface domain while the lower 






Figure 13. Cartoon depiction of the x-ray structure of Human GR (A) (PDB code: 2aaq) (95) and E. coli GR 
(PDB code: 1ger) (B) (92) respectively. Both molecules are shown with the cofactor FAD in the active site. 
The crystal structure of the E. coli enzyme has been solved; however, structural details 
of the active site complexed with the substrate have not been elucidated (92). Authors believe, 
that the binding strengths of the carboxylates are diminished by the following residues: Asn-21, 
and Val-102 for the E. coli enzyme and Arg-37, and Asn-117 for the human enzyme (96). 
Comparing both enzymes there is a very strong conservation of the upper interface of 
approximately 92% with a 52% overall identity when taking into consideration the whole 
enzyme structure. In the case of the lower interface there is only a 37% conservation (94). The 
enzyme belongs to the family of FAD-dependent disulfide oxidoreductses which includes 
trypanothione reductase (TR) (92). 
GR MECHA!ISM OF ACTIO! 
 
GSSG H+ 2GSH NADP++ + +NADPH  
Scheme 7. Enzymatic reduction of oxidized GSH 
 
GR is a flavoenzyme which catalyzes the NADPH-dependent reduction of GSSG via 
disulfide exchange reactions involving two cysteine residues. GR accepts reducing equivalents 
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from NADPH into noncovalenty bound FAD to give FADH2 which is the form of the reduced 
enzyme. These electrons are then transferred to an internal disulfide bond between Cys-42 and 
Cys-47 in the active site. These reduced cysteins then catalyze the reduction of GSSG via a 
disulfide exchange reaction (92, 97). 
GLUTATHIO!E BIOSY!THESIS 
 
GSH is biosynthesized intracellularly in two consecutive steps (Scheme 8), first by the 
actions of γ-glutamylcysteine synthetase (γGCS) and then by GSH synthetase, where cysteine is 
usually the limiting substrate (98). 
L-Glu + L-Cys + ATP    L-γ-Glu-L-Cys + ADP + Pi   (A) 
L-γ-Glu-L-Cys + ATP + Gly           GSH + ADP + Pi (B) 
Scheme 8. Biosynthesis of GSH 
There is a high demand for ATP in GSH synthesis which makes industrial scale up to 
produce this biochemical difficult. As a result, extensive research has been focused on 
simultaneously improving both GSH biosynthesis and ATP generation. However, the best 
method of producing GSH has resulted from application of a co-coupling ATP generation system 
(99). In this case, the ATP-requiring reaction is coupled with ATP-producing reactions that may 




γ-Glutamylcysteine synthetase (γGCS; L-glutamate: L-cysteine γ-ligase, EC 6.3.2.2) 
catalyses the first step in the GSH biosynthesis pathway which so happens to be the rate limiting 
step.  γ-GCS belongs to the glutamine synthetase superfamily and exsits as a heterodimer (100). 
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Even though no significant sequence homology exists between the mammalian and prokaryotic 
enzyme, their kinetic properties are generally similar (101). The enzyme appears to be regulated 
by allosteric feedback inhibition by GSH. Under various physiological conditions the enzymatic 
expression is controlled by transcriptional and posttranscriptional modifications (102, 103). 
γ-GCS has been purified from numerous sources (100, 104). The gene has been cloned 
and expressed in E. coli. For the mammalian system the gene for the rat kidney enzyme was first 
cloned and sequenced. The crystal structure solved for the E. coli enzyme consists of a catalytic 
domain and a small domain. The domains are linked by swapping their terminal short chains 
with each other and through a disulfide bridge. The catalytic domain has six anti-parallel β-
sheets that form a curved partial barrel with a funnel shaped internal cavity as depicted in figure 
14 (105). 
There are some conserved sequence regions between the prokaryote E. coli enzyme and 
the eukaryotic plant enzyme and this includes the active sites (105, 106). These suspicions were 
confirmed after the three dimensional structures of the enzymes were determined. The primary 
sequence produces a six-stranded anti-parallel-β-sheet that forms a bowl-like structure flanked by 
helical regions. The central part of both enzymes superimpose well. Unique to the plant enzyme, 
however, is a β-hairpin motif that is stabilized by a disulfide bridge. The active site is located at 
the bottom of a cavity easily accessible to solvent and the active site is formed by two arm-like 
structures flanking the central β-sheet. In addition to this, linking both the N and C terminal is 
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another disulfide bridge. 
 
   (A)       (B) 
Figure 14. Crystal structure of γ-GCS from E. coli (A) (PDB code:1v4g ) (105) and crystal structure of plant 
glutamate cysteine ligase (B) (PDB code: 2gwd)(106) 
 
γ-GCS CATALYTIC MECHA!ISM 
 
The catalytic mechanism proposed in scheme 9, shows the initial activation of the γ-
carboxyl group of L-Glu by ATP-phosphorylation leading to the formation of a γ-
glutamylphosphate intermediate. This step is followed by a nucleophilic attack of the amino 
group of L-Cys on the carbonyl that leads to the generation of a tetrahedral intermediate (107). 

































Glutathione synthetase (GS; EC 6.3.2.3) catalyses the ATP-dependent formation of 
GSH from γ-glutamylcysteine and glycine (85, 108). With respect to kinetics, the rat kidney 
enzyme has the highest specific activity of all GS so far reported and is highly specific for 
glycine and the cysteinyl moiety of γ-glutamylcysteine but has little specificity for the γ-
glutamyl moiety. 
The human enzyme has received much attention as it is linked to a type of hereditary 
disease. The enzyme is a homodimer of 52 kDa subunit molecular weight with sequence 





       (A)              (B) 
Figure 15. Crystal Structure of human (A) (PDB code: 2hgs )(108) and E. coli (B) (PDB code: 2glt) GS 
enzymes(110)  
 
GS has been purified from several sources (85). Interestingly there is no significant 
sequence similarity between the human and prokaryotic counterpart such as that from E. coli. 
The E. coli enzyme exists as a tetramer  comprising four identical subunits each with 316 amino 
acids (110, 111). The crystal structure of the E. coli enzyme has been solved (112). It is the first 
member of the ATP-grasp superfamily (113). Two subunits form a dimer and then the two 
dimers form a tetramer. There are three domains in each subunit the 3-, C- and central terminal 
domains. The first consists of a six-stranded β-sheet sandwiched between two α-helices. This β-
sheet has both a parallel and an anti-parallel arrangement. This domain also has a small α-helix 
and 310 helices. The central domain is composed of a four-stranded anti-parallel β-sheet and two 
α-helices which are located on the same side of the β-sheet. The C-terminal domain consists of a 






GLUTATHIO!E SY!THETASE CATALYTIC MECHA!ISM 
 
The GS superfamily has the common feature of exhibiting carboxylate-amine/thiol 
ligase activity and this can act on a wide variety of substrates (114). These enzymes catalyse the 
ligation of γ-Glu-Cys and Gly with the aid of ATP in the presence of Mg2+ ion. The reaction 
mechanism is proposed to be a peptide ligation reaction proceeding via two steps by analogy 
with other ligases (115, 116). First, phosphorylation of the C-terminal carboxylate of γ-Glu-Cys 
by the γ-phosphate group of the ATP to form an acylphosphate intermediate occurs, this then 
leads to the formation of a tetrahedral carbon intermediate (108). Then, dissociation occurs to 
release inorganic phosphate and ADP and formation of GSH (108, 116). A molecular basis for 
this proposed mechanism lies in the crystal structure data from the human enzyme which 
indicates that residues that form polar interactions with ATP, Mg2+ and GSH are strictly 



























































 Scheme 10. Reaction mechanism of GSH synthesis 
 
γ-GCS A!D THE GS SUPERFAMILY 
 
Researchers have looked at the sequence alignments for γ-GCS enzymes from various 
fungi, plants and bacteria. Their results suggest high homology among all γ-GCS. The γ-GCS 
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homologues have been divided into two eukaryotic groups, EI and EII, and into three prokaryotic 
groups due to the difficulty of detecting significant sequence homology among the groups of 
proteins from varied organisms (117). In the case of the GS enzymes from the same group of 
organisms, the key residues for metal and substrate binding and activation form highly conserved 
motifs that are mainly located in the central β-sheet. There is, however, conservation of key 
residues when comparing some of the γ-GCS and GS family members. Hydrophilic and 
hydrophobic positions alternate along the predicted β-strands showing that these proteins can be 
classified under the carboxylate-amine/ammonia ligase superfamilies. These superfamilies are 
extremely diverse and range from 7-92% in sequence identity making branching on a proposed 
phylogenetic tree highly unreliable (117). 
ORGA!ISMS WITH A !O!-GLUTATHIO!E REDOX SYSTEM  
 
GSH is extremely important in maintaining cellular redox potentials and protein thiol-
disulfide ratios. GSH is the major intracellular thiol in many organisms. In E. coli, under 
stationary phase and anaerobic conditions, 80% of the GSH in E. coli is transformed to 31-
monoglutathionylspermidine (GspdSH) (118). In addition to this, there are some organisms 
where GSH does not act as the major intracellular thiol  especially in several major classes of 
Gram-positive bacteria, and in Trypansomatids (119) and in Actinomycetes where it is not 
detected at all (120). In the latter, GSH is not present in most Streptomyces which are agents for 
antibiotics such as one known species of Nocardia which contains penicillin, cephalosporin, and 
cephamycin antibiotics. Instead they utilize the cofactor mycothiol (MSH) (shown in Figure 16) 
(121, 122). 
There are organisms, (such as the trypanosomes and leishmania) that are extremely 
parasitic protozoa that are the culprits for inflicting death, despair and economic devastation 
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(123) resulting from African sleeping sickness (Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense), Nagana cattle disease ( Trypanosoma congolense, 
Trypanosoma brucei brucei), South American Chagas’ disease (Trypanosoma cruzi), or different 
forms of leishmanias. Any information on the biochemistry related to trypanothione is an 
excellent target for drug design and study as rendering trypanothione useless to the organism 
would be an excellent target for antitrypanosomal and antileishmanial agents (124).  
Table 2. Amount of people affected by diseases caused by some trypanosomes and leishmanias.  
Pathogenic Organism !umber of People Affected 
Leishmania 12 million (78) 
Trypanosoma cruzi 18 million (75)  
African Trypanosomes 300 000 – 500 000 (79) 
 
These protozoa (trypanosomatids) differ from all other known eukaryotes and 
prokaryotes because they contain a unique redox system that utilizes the thiol polyamide 
conjugate trypanothione (T(SH)2), and T(SH)2 reductase (125-127). It is clear now that the 




















































































1,38-bisglutathionyl)spermidine) was first discovered in 
1985 (126) and identified as a bis-glutathionyl derivative of spermidine. It was discovered when 
Fairlamb et al. detected an unusual GSH reductase activity in the African trypanosome, 
Trypanosoma brucei brucei (126).The enzymes from the cell free extracts were unable to reduce 
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GSSG in the presence of NADH unless an unidentified cofactor was present. It was later 
discovered that this cofactor was T(SH)2. It was identified by amino acid analysis, mass 
spectrometry, and chemical synthesis after its isolation and purification (125).  
COMPARISO! OF GLUTATHIO!E A!D TRYPA!OTHIO!E 
 
It is now known that T(SH)2 replaces the role of GSH in organisms such as the 
Trypanosomes (128). It is also known that GSH is a precursor to T(SH)2 in these cells. Evidence 
indicates that only about 10-30% of the total amount of GSH in these organisms is present as 
free peptides. Therefore, most of the GSH produced in these organisms are immediately 
converted to T(SH)2.  
TRYPA!OTHIO!E REDUCTASE 
 
Many of the antioxidant properties of T(SH) 2 occurs in its dithiol form; in the cell this 
is promoted by the enzyme trypanothione reductase (TR; EC 1.6.4.8) (129). TR has been isolated 
and studied in and from many species (130-132). Trypanosomatids do possess other thiols in the 
cell: GSH, mono-glutathionlyspermidine and ovothiol (133-135). All of these dithiol forms are 
either directly or indirectly reduced by TR. In the former case, TR directly utilizes T(SH) 2 and 
mono-GspdSH as substrates, and indirectly spontaneous reactions of glutathione disulfide and 
ovothiol occur in the cell and the resulting substrates are transformed by TR (127). 
TR is an extremely important enzyme in the trypanosomatids. Using an inducible 
expression system in blood stream cells, TR gene expression has been controlled under a 
tetracycline-inducible promoter which allowed TR regulation from 1-400% of the wild type level 
(136). In the absence of tetracycline, the inducible knockout cell line was unable to infect mice. 
In addition to this, the trypanosomes that contain less than 10% of wild type activity did not 
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grow even though levels of T(SH)2 and total thiols did not change. When the media did not 
contain reducing agents, these mutant parasites became hypersensitive to hydrogen peroxide 
(127, 136). These observations indicate that the de novo synthesis of TSH and the residual TR 
activity are sufficient for maintaining thiol redox potential but prove to be lacking when the 
organism has to cope with oxidative stress (127). 
Novel discoveries indicate that both TR and GR are present in the phytoflagellated 
protozoan Euglena gracilis which belongs to the euglenoid subphyllum of Euglenozoa (137). 
This was the first and only report of an organism that possesses both TR and GR (127).  
Thus far TRs from trypanosomes are somewhat similar to GRs in their overall 
structure. Both are homodimeric proteins with approximately 50 kDa per subunit. FAD is present 
as a cofactor and the enzyme is specific for NADPH as an electron donor. TR contains a redox-
active cysteine disulfide in the active site (138-141).  
BIOSY!THESIS OF TRYPA!OTHIO!E 
 
Until the 1990s it was thought that only a single enzyme was necessary to produce 
T(SH)2 from GSH and spermidine (spd) coined trypanothione synthetase (142). However, it is 
clear that there are two ATP-dependent pathways in which the 31, 38 isomers of the GspdSH are 
intermediates (143). This puzzle has now been resolved as two separate and distinct enzymes: 
glutathionylspermidine synthetase (GspdS) and a trypanothione synthetase (TS) (129).  
Biosynthesis of T(SH)2 can therefore be subdivided into three steps: the production of 
GSH, spermidine and then finally the resulting combination T(SH)2. (see figure 5) (127). 
Production of GSH in trypanosomes seems to follow the same sequence as in the mammalian 
enzymes. However, preliminary examination of the substrate binding pocket and enzyme 
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regulation of γ-GCS differ when compared to the aforementioned synthesis pathway in GSH-
utilizing organisms. This enzyme is also feedback inhibited by GSH (144).   
 




Initial studies on trypanothione synthetase (TS; EC 6.3.1.9) was reported based on 
studies in the organism Crithidia fasciculata. Here, T(SH)2 biosynthesis occurs by the action of 
two distinct enzymes as aforementioned. Scientists who discovered TS would be comforted to 
know that there is in fact unique TS enzymes that catalyses the formation of T(SH)2 in a single 
step as it catalyzes both T(SH)2 and Gspd from GSH. Both enzymes are found in T. brucei, and T 
cruzi (138). 
The enzyme from T. brucei is approximately 72 kDa with a Km of 56 ± 10µM. These 
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PRESE!CE OF GLUTATHIO!YL SPERMIDI!E 
 
Over 30 years ago, Tabor et al. discovered in E. coli a novel glutathione and spermidine 
conjugate, 31 monoglutathionylspermidine (GspdSH) (145). It is to date, known to be present 
only in the late log or stationary growth phase of the organism (118, 145). This is a very 
important achievement as this thiol is known to be present in organisms where it is a precursor to 
other thiols in the case of the trypanosomatids and a group of flagellated protozoa which consists 
of many human pathogens as will be discussed later. (118). This calls into question the substrate 
specificity of the enzymes involved in E. coli metabolism and overall the actual purpose of this 
metabolite in E. coli. 
Comparing the presence of GSH and Gspd in the E. coli growth phase, Fairlamb and 
others determined that of the total GSH present in the cell, 80% is present in the form of Gspd 
disulfide (GspdS)2in its reduced form (GspdSH) (118). At this stage of growth the cell is under 
duress, it is suggested that synthesizing Gspd might be one way in which the level of the 
precursor metabolites, spermidine, and GSH might be regulated in the cell (145). It also is of 
significant importance to determine if this newly synthesized thiol is able to act as a better DNA 
protector. It may serve to be more efficient in protecting against radical or oxidant-reduced 
damage (118, 146). The cellular levels of GSH and GspdSH are dependent on the rate of 
biosynthesis and turnover. This would indicate that when the cell senses environmental stress the 
rate of GspdSH increases as it is also detected in the mid-log phase as well, albeit at lower 
concentrations (118).  
Even though T(SH)2 forms the basis for trypanosomes and leishmania metabolism it is 
interesting to note that sometimes cellular concentrations of GspdSH are higher than T(SH)2 and 
can even rise to approximately 2.5 mM in the organism Crithidia fasciculata (147). As the cells 
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of T. brucei grow, the presence of GSH increases so much that at the late log phase the 
concentration of free GSH in solution (1.2 mM) (148) is much greater than that of T(SH)2 (340 
µM) (133). Even the organism L. donovani contains approximately 1.8 mM of free GSH (149). 
There are two main theories why this might occur (150). The organism could be using the free 
GSH to synthesise GspdSH at rapid levels, this could be used so quickly which would make 
detection of GspdSH difficult, and also for glutathionylation of thiol redox proteins (150). This 
phenomenon is a means for the cell to protect proteins in metabolism against oxidative stress (87, 
150, 151). 
Thiols function as redox agents, and they can be easily oxidized. It is interesting then to 
indicate that a glutathionylspermidine reductase ((GspdS)2R; EC 1.6.4.2) has not been found in 
E. coli as yet. This begs the question as to how does this organism efficiently regenerate 
GspdSH. In Scheme 11., it is proposed that (GspdS)2 undergoes a thiol exchange with GSH to 
form the mixed disulfide (118). Analysis of the kinetic properties of the mixed disulfide indicate 
that it may be a physiological substrate for GR (118). There is also the possibility that the 
disulfide may undergo further thiol-exchange with GSH and this regenerates the second GspdSH 
molecule (118). The rates of these reactions whether non-enzymatic or possibly enzymatic, will 
of course depend on the actual cellular concentrations of the mixed disulfide, (GspdS)2, and 
GSH. Further information in this area is definitely needed as reports exist showing normal thiol 

















Scheme 11. Proposed mechanism for the reduction of (Gspd)2 in E. coli (152)  
 
GLXI FROM TRYPA!OSOMES 
 
Leishmanias and Trypanosomatids all contain a glyoxalase system which has been 
determined to be T(SH)2 dependent (153). Current chemotherapeutic agents for these organisms 
can be toxic to humans and drug resistance has been observed. Targeting the glyoxalase enzymes 
in these organisms with inhibitors may add to the number of useful chemeotheraputic agents 
available to treat these protozoans (154).  
Thus far in these trypanosomes, the GlxI enzymes has been found to require a metal 
cofactor. The native enzyme contains Ni2+ and is most active with Ni2+ and Co2+ and this profile 
si similar to the E. coli GlxI enzyme while the mammalian enzymes are most active with Zn2+, a 
metal that inactivates their prokaryotic counterparts. It is also important to note that the 
differences in the dependence of the metal cofactor might be due to the differences of the active 
sites of the human and leishmanial enzymes for example and therefore these prokaryotic 
enzymes may be a target for antimicrobial therapy (59, 64). 
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SEQUE!CE A!ALYSIS OF THESE GLXI E!ZYMES 
 
From sequence alignments, it is observed that there are many similarities between the 
T(SH)2 dependent GlxI and those of the E. coli and human GlxI enzymes. Observing figure 18, 
the active site residues are all conserved in all of the proteins with the exception of the histidine 
located at position 34 in the alignment which corresponds to a glutamine in the human sequence. 
These are the metal binding residues and may be the cause of the replacement of Zn2+ in the 
active site rather than Ni2+. In reference to identity, L. donovani shows an approximate 96% 
identity to L. major and L. infantum, a 73% identity to T. cruzi, 49% identity to E. coli, and 33% 
identity to the human enzyme (154). 
PROPOSED SUBSTRATE BI!DI!G 
 
In addition to this there are a few residues thought to be involved in substrate binding in 
the trypanosomes and are indicated with small triangles at positions 100 and 101 in the sequence 
alignment. Researchers have found that these residues are conserved among all trypanosomes 
whose GlxI sequences are known. However if these were the substrate binding residues in E. coli 
then it would be expected that they would show some similarity to the human enzyme as the 
same substrate hemithioacetal is used; but, this is not the case. This region is proposed to be the 
substrate binding loop in the human enzyme. When a superposition of Cα traces of the crystal 
structure of E. coli GlxI and a model of GlxI from L. donovani was undertaken, it indicated that 
there was a significant difference in the size and shape of this region (154). Examining the 
human enzyme more carefully, there are three critical residues that should be noted: Arg-37, His-
103 and Arg-122 that are involved in the binding of nitrobenzyloxycarbonylglutathione, and 
inhibitor (59). Only position 37 is conserved among all the enzymes while position 103 is 
conserved as tyrosine in the prokaryotes.  
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In the L. major GlxI active site, the γ-glutamate metal binding residues are highly 
conserved among the parasites as well as for E. coli and the human enzymes while the MG 
pocket and the glycyocarboxylate or amine-binding residues have significant differences (155). 
The residues that bind the γ-glutamate moiety of the substrate are indicated by squares. Here, the 
Oδ2 and Nδ1 atoms of the Asn residue coordinate the γ-glutamate’s primary ammonium and 
carboxylate groups respectfully (155, 156).  
SUBSTRATE SPECIFICITY 
 
The proposed fundamental difference in the substrate specificity between GSH and 
T(SH)2 binding enzymes is based on their individual interaction of the small and negative glycyl 
carboxylate in the GSH, or the larger positive or aliphatic containing glycyl-spermidine amide 
with reference to T(SH)2 (155). When examining TR, there is a discrimination facilitated by an 
enlarged active site due to a substitution of a cluster of mainly polar or positively charged 
residues for hydrophobic or negatively charged residues (157). With GlxI, human x-ray 
structures with inhibitors bound (57, 59) indicate that the glycl carboxylate is either not directly 
coordinated by protein or it interacts with backbone nitrogen atoms (155). This region, β6 and β7 
in the human enzyme is truncated in the L. major and this may allow for the larger spermidine 
moiety which would permit the glycyl amide to coordinate to the protein backbone just as would 
the glycyl carboxylate in the human enzyme (155).  
The spdSH moiety is a highly flexible molecule and may have two conformations in the 
active site: either away from the active site pockets or towards them. There are variable sequence 
positions at the C-terminal end of the β6 peptide which may be an underlying factor in ligand 
discrimination. The residues Asp-100 and Tyr-101 are present in L. major which is conserved 
among all the trypanosomes shown but is replaced with a valine and arginine in the human 
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enzyme and threonine and lysine in the E. coli enzyme. The negative charge of Asp-100 is highly 
favorable in binding of the positively charged nitrogen atoms which are suitable for binding 
spermidine’s secondary and tertiary ammonium groups (155). This is in contrast to the human 























                               20                    40              
                *                               *  ♠  *  * * *♠       
T. cruzi    MSTRR----- ---------- ---------- -LMHTMIRVG DLDRSIKFYT 24 
L. major    MPSRR----- ---------- ---------- -MLHTMIRVG DLDRSIKFYT 24 
L. donovani MPSRR----- ---------- ---------- -MLHTMIRVG DLDRSIKFYT 24 
L. infantum M--------- ---------- ---------- --LHTMIRVG DLDRSIKFYT 19 
E. coli     M---R----- ---------- ---------- -LLHTMLRVG DLQRSIDFYT 21 
H. sapiens  MAEPQPPSGG LTDEAALSCC SDADPSTKDF LLQQTMLRVK DPKKSLDFYT 50 
                                                ●   ■                 
 
                     60                    80                   100   
                   **      *   ♠     * * *                    ϙ* |    
T. cruzi    EALGMRLLRK WDCPEDKFTL VFLGYGTE-- ---------- ---SETAVLE 59 
L. major    ERLGMKVLRK WDVPEDKYTL VFLGYGPE-- ---------- ---MSSTVLE 59 
L. donovani ERLGMKVLRK WDVPQDKYTL VFLGYGPE-- ---------- ---MSSTVLE 59 
L. infantum ERLGMKVLRK WDVPQDKYTL VFLGYAPE-- ---------- ---MSSTVLE 54 
E. coli     KVLGMKLLRT SENPEYKYSL AFVGYGPE-- ---------- ---TEEAVIE 56 
H. sapiens  RVLGMTLIQK CDFPIMKFSL YFLAYEDKND IPKEKDEKIA WALSRKATLE 100 
                                                                 ●     
 
                               120                   140           
              * ♠             ϙ *     *   *        *             ▲     
T. cruzi    LTYNYGQS-- ---EYKHGDA ----YGHIAI GVEDVNEEIA RLKKMNVPID 100 
L. major    LTYNYGVT-- ---SYKHDEA ----YGHIAI GVEDVKELVA DMRKHDVPID 100 
L. donovani LTYNYGVT-- ---SYKHDEA ----YGHIAI GVEDVKELVA DMRKHDVPID 100 
L. infantum LTYNYGVT-- ---SYKHDEA ----YGHIAI GVEDVKELVA DMRKHDVPID 95 
E. coli     LTYNWGVD-- ---KYELGTA ----YGHIAL SVDNAAEACE KIRQNGGNVT 97 
H. sapiens  LTHNWGTEDD ATQSYHNGNS DPRGFGHIGI AVPDVYSACK RFEELGVKFV 150 
               ■                        ●                              
 
                    160                   180                      
            ▲*      *       ◊          *                           
T. cruzi    YES---EDG- -FMAFIVDPD GYYIELLNTE RMLEKSREQM NEQGTA 141 
L. major    YED---ESG- -FMAFVVDPD GYYIELLNEK TMMEKAEADM KEQGTA 141 
L. donovani YED---ESG- -FMAFVVNPD GYYIELLNEK MMMEKAEADM KEQGTA 141 
L. infantum YED---ESG- -FMAFVVDPD GYYIELLNEK MMMEKAEADM KEQGTA 136 
E. coli     REAGPVKGGT TVIAFVEDPD GYKIELIEEK --------DA GRGLGN 135 
H. sapiens  KK--PDDGKM KGLAFIQDPD GYWIEILNPN KM-------- --ATLM 184 
                                      ●                            
 
Figure 18. Sequence alignment of some GlxI enzymes  
 
T. cruzi (Tc00.1047053510659, L. major (LmjF35.3010), L donovani (accession number AAU87880), L. infantum 
(accession number LinJ35.2600), E. coli (accession number P77036), and H. sapiens (accession number P78375). 
The circles display conserved metal binding residues, the filles squares are associated with residues postulated to be 
involved in the binding of γ-glutamate moieties of thiol cofactors while the triangles indicate some conserved acidic 
residues in the tryoanosomes that are thought to be involved in the binding of T(SH)2. Conserved residues are 








STRUCTURAL A!ALYSIS OF TRYPA!OSOMAL GLXI 
 
Crystal structures have been solved for L .major (155) and T. cruzi enzymes. The global 
structure of the L. major GlxI is more comparable to that of the E. coli enzyme rather than the 
human enzyme in that it is a homodimer that contains two βαβββ domains with substrate 
coordination participation from both domains (155). There are however, two significant 
structural differences from both the human and E. coli enzymes in that the loop between β6 and 
β7 is shortened by seven and five residues with respect to the E. coli and human enzyme 
respectfully. There is also a 15 residue helix present at the C-terminus of L. major GlxI that is 
not present in the E. coli enzyme and this differs from the C-terminal helix of the human enzyme 
as it is ten residues shorter (155).  
ACTIVE SITE STRUCTURE A!D METAL COORDI!ATIO! 
 
It is proposed that the active site alters during substrate binding. Glutamic acid in the 
human enzyme contains a six coordinate ligand system with two water molecules there is 
evidence that this becomes a five coordinate system upon substrate binding (64). This occurs at 
Glu-173 which corresponds to Glu-122 in the E. coli enzyme. This residue is conserved among 
all the parasitic prokaryotes whos sequences have been determined and therefore this 
mechanistic theory may hold true for all GlxI enzymes displayed (64). Other substrate binding 
sequences have not been determined for E. coli. It may be proposed that in the positions 
indicated by spades in figure 18 may also be valid suggestions for the enzyme’s specificity for 
GSH vs GspdSH and T(SH)2 hemithioacetals (64). 
The trypanosome T. cruzi GlxI is at first inspection, suggestive of Ni2+ activation based 
on comparison with this enzyme’s prokaryotic counterparts. Greig and coworkers however, 
found significant reactivation of the T. cruzi enzyme by Co2+, Mn2+ and Zn2+(156). It is 
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suggested that this enzyme’s versatility stems from the differing bioavailability of metal 
cofactors in the mammaliam hosts in which it is parasitized (156). Its prokaryotic counterpart L. 
major is also reactivated to a much lesser extent with Co2+ and Mn2+ but is not versatile enough 
to be reactivated by Zn2+ (153). 
There are significantly different active site structures among the human, E. coli and L. 
major enzymes. The E. coli GlxI has a narrow tube, L. major an open groove, and H. sapiens is 
shaped like a small cup ( see (155) for more detailed information) which justifies the specificities 
among the enzymes (155). 
The chemical mechanism for GlxI requires an octahedrally coordinates divalent metal 
ion and in this case is Ni2+ (for the E. coli enzyme). This metal coordinated the two oxygen 
atoms of the glyoxal moiety of the substrate which then polarizes them and facilitates the 
rearrangement, via an enediolate intermediate (67). In addition to His-8, His-77, Glu-59, and 
Glu-120, there are two water molecules coordinating the metal ion in the active site (155). 
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T(SH)2 and GspdSH proved to be the best substrates for the GlxI enzymes from L. 
major, T.cruzi, L. donovani and L. infantium in all cases a high kcat/Km (greater than 107) is 
observed for both substrates. The GSH hemithioacetal substrated of MG proved to be very poor 
substrates as the GspdSH and T(SH)2 hemithioacetals were 2400-fold and 14000-fold times 
respectfully more effective in T. cruzi (154) and GspdSH was 280-fold more effective with L. 
major GlxI (155). In L. infantum T(SH)2 is present in a 6:1 ratio when compared to GSH which 

































































































































































































































































































































































































GLXII FROM THE TRYPA!OSOMES 
 
In the second step of the glyoxalase system, GlxII hydrolyzes the thioester produced 
from the GlxI reaction producing D-lactate in the process. Studies in this area are very limited but 
recently there are some trypanosomal GlxII enzymes that have been found to be T(SH)2 
dependent such as that of T. brucei, L. donovani, and L. infantum (159). 
SEQUENCE ANALYSIS 
In T. brucei for example, the GlxII deduced sequence contains 296 amino acid residues 
and has a 66% and 51% similarity to the putative GlxII proteins from T. cruzi, and L. major 
respectfully as well as 36% and 31% to the human and Arabidopsis thaliana GlxII respectfully. 
In addition, there is a 30% sequence similarity with that of E. coli GlxII (160). GlxII from L. 
infantum for example shows a 99.5% sequence similarity with the enzymes from L. donovani, a 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































METAL BI!DI!G OF THE TRYPA!OSOMAL GLXII E!ZYMES 
 
There is a highly conserved metal binding motif THXHXDH detected among GlxII 
enzymes as seen in figure 20 (161, 162). There are five histidines, and two aspartic acid residues 
that interact directly with the two metal ions (69). The sequence similarity suggests that the 
prokaryotic counterparts are also metalloproteins. Metal analysis of the recombinant T. brucei 
protein confirmed the presence of zinc in the active site even though iron may also be present 
(69). As the isolated human enzyme contains a Zn2+ metal ion even though the authors postulated 
that it could also be actived by Fe2+ (69). The GlxII enzyme from A. thaliana exhibits an iron-
zinc binuclear site which appears to be needed for catalysis (163). Studies have shown that the 
enzyme is versatile with respect to its metal activation as it is able to incorporate Zn2+, Fe 2+ or 
Mn2+ depending on the culture medium used to grow cells. The resulting metalated GlxII are 
catalytically efficienct (164).  
SUBSTRATE BI!DI!G 
 
The crystal structure has been solved for the GlxII from L. infantum (162). This 295 
amino acid metalloprotein has a structure similar to that of its human counterpart with the 
exception that there is an extra β strand at the 3-terminal and extra α helix located at the C-
terminal domain. This crystal structure was obtained complexed with D-lactate which is located 
between the metal ions which are separated at about 3.58 Å. The D-lactate is bound to the metal 
ions through its O3 atom which is at distances of 2.3 and 2.68 Å respectfully from metals 1 and 2 
and also through its O1 and O2 atoms at a distance of 2.87 and 2.14 Å respectfully (see figure 
21).  
Based on the crystal structure of human GlxII, the residues for substrate binding are 
thought to be Arg-249, Lys-252, and Lys-143. When the enzyme is complexed with a substrate 
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analogue, these three residues interact with the thioester and are in the close proximity to the 
glycine carboxylate of the glutathione moiety of the substrate analogue (69). These residues are 
conserved among the GlxII enzymes, but are not present in the L. infantum (162) nor T. brucei 
and other kinetoplastids GlxII enzymes (159). This maybe the difference in substrate specificity 
of the enzymes as the latter GlxII enzymes utilize the thioesters of T(SH)2 instead of GSH.  
The active site of L. infantum revealed a water molecule briding the two zinc metals 
(separated by 3.32 Å). The active site forms a tetrahedral coordination and is coordinated by the 
following residues: His-76, His-78, His-81, His-139 , His-210, Asp-80, and Asp-164 (162).With 
spermidine bound to the active site of GlxII from L. infantum, residues Ile-171, Ala-173, Tyr-
212, Phe-219, and Phe-266 assist in the interaction (162). The Phe-266 residue that interacts with 
the spdSH molecule is present in the extra α helix at the C-terminal domain but in the human 
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For T. brucei the catalytic efficiency of T(SH)2 thioesters are comparable with other 
enzymes such as C. albicans catalysis with the GSH thioester (159, 165). GlxII from L. infantum 
exhibits a marked preference for the thioesters of T(SH)2 and GspdSH rather than GSH as the 
latter displayed no activity under assay conditions (162). The results do show that thioesters of 
GspSH are the preferred substrate in these enzymes even though T(SH)2 is present at higher 
concentrations under normal cell conditions (162). Studies with L. donovani GxII do not indicate 
GspdSH can act as a substrate but does confirm that the thioester of T(SH)2 is more preferred 
with respect to the GSH containing substrate (166).












































































































































































































































































































METHODS A!D RESULTS 
 
The thiols under study were GSH, GspdSH and T(SH)2. In order to obtain 
reproducible data the natural substrate was assayed to confirm previously published 
results (61). No reports are present to date that gives Gspd a function other than being a 
precursor for other thiols such as T(SH)2. In E. coli, however, T(SH)2 is not present and 
thus the function of Gspd in E. coli has eluded scientists for some time. One could 
speculate that since it is formed under cell duress, it may be used in the glyoxalase 
system as a co-substrate since it could be more reactive than glutathione. One could 
further speculate that this act by the organism has some effect on DNA protection of cells 
and maintenance of thiol redox ratios occurring under environmental stress. Previous 
work indicates that there is a correlation to the rate at which GspdSH is produced in 
relation to the growth phase of the organism (118). 
In organisms such as the trypanosomatids, GSH is present but most of the GSH 
is used to make T(SH)2. Previous studies using the glyoxalase system from Leishmania 
indicate that GSH is a poor substrate for the GlxI of that organism (126). However, broad 
substrate specificity is known to be associated with the E. coli enzymes such as the 
glutathione reductase that does take T(SH)2 as a substrate. It would therefore be 
interesting to discover just how broad is the substrate specificity for this E. coli enzyme 






Figure 22. Protocol for obtaining kinetic data for alternate substrates of GlxI. 
MG PURIFICATIO! 
 
MG purification was undertaken as previously describes (60). In brief, 
commercialized MG (40% aqueous solution) was distilled to remove any polymers and 
other contaminants that may have formed in solution over time. This solution was 
distilled at atmospheric pressure but the purified MG was obtained between 92-96˚C 
(167). This stock could be stored for up to six months, however MG was calibrated on a 
monthly basis to ensure polymerization did not occur while in storage at 4˚C. 
MG CALIBRATIO! 
 
MG was calibrated by running the glyoxalase assay in triplicate and monitoring 







Thiol Reduction Thiol Calibration 








approximately 150-fold. To a final assay volume of 300 µL, four MG concentrations 
were tested in triplicate by aliquoting different volumes into eppendorf tubes. This 
solution was then incubated with GSH (adding 10µL of a stock concentration of 50 
mg/mL in each reaction mixture). This substrate solution was incubated in 100 mM 
potassium phosphate buffer (KPB) pH 7.0 for approximately15 minutes until activated 
for the production of S-D-lactoylglutathione by the addition of 0.1 units of yeast GlxI 
grade IV from Sigma. Here, one unit of enzyme is equivalent to an activity of 1mmol of 
S-D-lactoylglutathione produced per minute (168). The solutions were monitored using an 
absorbance detecting plate reader at 240 nm for the production of S-D-lactoylglutathione 
with an extinction coefficient of 2860 M-1cm-1 (60).  
PURIFICATIO! OF GLYOXALASE I 
 
BACTERIAL GROWTH A!D HARVEST 
 
Conditions for growth and overexpression of wild-type E. coli GlxI were done 
as previously described (60). A starter culture of 10 mL was grown overnight with 
ampicillin (50 mg/mL) or carbenicillin (50 mg/mL) at 37˚C. Then this culture was added 
to a 1L batch of sterile Luria-Bertani (LB) broth and grown with additional carbenicillin 
or ampicillin keeping the concentration constant. To this culture a small amount of NiCl2 
was added to a final concentration of 1mM and then shaken at 37˚C. The culture density 
was concurrently checked until it had an optical density of approximately 0.5 at 600nm. 
Approximately 6 hrs later, GlxI overexpression was then induced using IPTG with a final 
concentration of 0.5 mM. This culture was left to incubate while shaking for 6-8 hrs 
before harvesting the cells. 
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This sample was then centrifuged in a Beckham JA-14 rotor at 10 000 rpm for 
30 minutes at 4˚C. Cells were then resuspended in 20 mM Tris buffer at pH 7.0, a second 
round of centrifugation was performed at the same conditions. The retrieved pellet was 
then flash frozen using liquid nitrogen and stored at -80˚C.   
CELL LYSIS 
 
Cell samples were left to thaw on ice with the addition of PMSF (1mM final 
concentration) and resuspended in 20 mM Tris buffer pH 7.5 and 10% glycerol with a 
concentration of approximately 10 g/mL cells. These cells were then lysed by sonication 
using 30 pulses of 10 second duration with intermittent cooling on ice for approximately 
1 minute. The final cell debris was then placed in a JA 25.50 rotor and spun at 20 000 
rpm for 15 minutes at 4˚C. 
CHROMATOGRAPHY 
 
The supernatant from the above procedure was first processed by anion 
exchange chromatography by application to a 10/30 Q-Sepharose Fast Flow column at 
0.8 mL/min. The column was first equilibrated with buffer A (20 mM Tris pH 7.5, 10% 
glycerol), the protein was eluted using a linear gradient of buffer B containing 1M KCl. 
GlxI fractions were pooled and dialysed against 2 x 1L 20 mM Tris pH 8.5 and then 
passed through another anion exchanger 5/5 Mono Q with a flow rate of 0.5 mL/min 
using a liner gradient of KCl with 1 mM PMSF and 10% glycerol pH 7.0. GlxI fractions 
were pooled for dialysis (overnight) against 2 x 1L Milli-Q water and 10% glycerol with 
1 mM PMSF. In all instances, the GlxI fractions were identified by SDS PAGE and the 
dialysate placed in a SPECTRA/POR® dialysis tubing with a molecular weight cut off of 






Preparative isoelectric focusing was next performed to de-metalate the enzyme. 
The cell was first run with Milli-Q water at 2W constant power for 20 mins to remove 
contaminating ions. Then, the cell chamber was filled with the protein sample, and 
Biolyte ® 4/6 ampholyte (MES and glycylglycine) solution with a final concentration of 
100 mM that established a pH gradient of 4.5-5.0 and Milli-Q water. This solution was 
then focused at 12 W constant power for 6 hours and harvested. Aliquots of these 
fractions were then subjected to trichloroacetic acid (TCA) precipitation and then 
identified by SDS-PAGE.  All pooled fractions were then concentrated by ultrafiltration 
utilizing an Amicon ® ultrafiltration device with a 10 kDa cutoff membrame. The protein 
was then exchanged into Chelex treated 50 mM MOPS pH 7.0 for storage for up to six 
months at 4˚C. 
PURIFICATIO! OF GLYOXALASE II 
 
BACTERIAL GROWTH A!D HARVEST 
 
The conditions for overexpression and growth of wild-type GlxII were followed 
as previously described (160). A 1 mL starter culture with BL21 (λDE3) pGloB was 
placed in a 1L sample of LB for growth. Both the starter culture and batch culture were 
supplemented with 50 µg/mL carbenicillin. This culture was then incubated at 37˚C until 
an optical density of approximately 0.7 was detected at 600 nm, then glx I expression was 
induced by the addition of IPTG (0.5 mM final concentration). This solution was then 
allowed to further incubate for approximately 4 hrs before harvesting. 
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The cells were recovered by centrifugation in a JA-10 rotor at 6000 g for 15 
minutes, then resuspended in 50 mM Tris pH 8 and then centrifugation was repeated at 
6000 g for 30 minutes, repelleted and then the pellet was flash frozen in liquid N2 and 
stored at -80˚C.  
CELL LYSIS 
 
The cell lysis conditions are similar to those aforementioned for GlxI. However, 
they differ in that the lysis buffer present was 50 mM Tris at pH 8 with the conditions for 
glycerol and PMSF unchanged. This solution was then diluted to 30 mL and applied in 
the following manner in triplicates by performing three 10 mL injections for all 
chromatographic applications with the exception of gel filtration chromatography in order 
to obtain a final sample of wild type E. coli GlxII.  
PROTEI! PURIFICATIO! 
 
Purification of GlxII was performed in a similar manner to GlxI. There were a 
few differences in the buffers used. The buffer used for Q sepharose ion exchange 
chromatography was 50 mM Tris pH 8.0 with 10% glycerol using a linear gradient of a 
second buffer containing 1M KCl to obtain GlxII fractions. Once obtained, these 
fractions were then pooled under the same dialysis conditions as described for GlxI with 
the exception of the buffer which was 50 mM Tris pH 6.5 with 10% glycerol. This was 
then applied to the Mono Q column and protein samples were eluted with a linear 
gradient of KCl. Fractions active for GlxII activity were then dialysed against 50 mM 
potassium phosphate buffer pH 6.5 under the same conditions as previously mentioned 
for dialysis.  
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This solution was then subjected to NH4 (SO4)2 precipitation. This was done by 
the addition of NH4 (SO4)2 crystals to a final concentration of 1.7 M stirring on ice over a 
period of 30 minutes. This sample was then left on ice stirring for an additional 30 
minutes. The resulting solution was centrifuged using a JA 25.5 rotor for 15 minutes at 
20 000 rpm.  
The supernatant was then filtered and loaded on a Phenyl HP Hi Sub column 
which was 1 mL total volume. This column was first equilibrated with 50 mM potassium 
phosphate buffer pH 6.5 containing 1.7 M NH4 (SO4)2. Samples containing GlxII activity 
were then retrieved using a decreasing linear gradient of NH4 (SO4)2, this was done over 
a 20 minute period with a flow rate of 0.5 mL/min. Samples were then identified using 
SDS PAGE, then dialyzed overnight under the same dialysis conditions as in GlxI against 
50 mM Tris pH 7.5.  
The samples obtained were then concentrated to approximately 100 µL and 
analyzed by gel filtration chromatography by application to Superdex 75 using an elution 
buffer of 50 mM Tris with 100 mM KCl. Samples that were positively identified for 
kinetic competence were then pooled and stored in 50 mM Tris pH 7.5 at 4˚ C. 
E!ZYME CALIBRATIO! 
 
Protein quantitation was performed using the dye-binding method of Bradford 
(169). The assay dye reagent consisted of 0.01 w/v Coomassie brilliant blue G-250, 95% 
ethanol and 10% phosphoric acid (85% w/v). Prior to use, the assay dye reagent was 
filtered through a Whatmann #1 filter and stored in the dark at 4˚C. 
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The assay was conducted by first creating a standardized curve using bovine 
serum albumin. Then three diluted concentrations of the protein sample were diluted in 
the Bradford solution in triplicates to determine protein concentration.   
PROTEI! A!ALYSIS, IDE!TIFICATIO! A!D STORAGE 
SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS ( SDS-PAGE) 
 
Screening of all samples during purification was done utilizing SDS-PAGE. The 
samples were first prepared by denaturing the protein. This was enabled by mixing a 
small sample in loading buffer (150 mM Tris, 2% SDS, 1% β-mercaptoethanol, 10% 
glycerol, 0.1% Bromophenol blue pH 8.0) with a 1:1 ratio and then boiled for 
approximately 20 mins. These samples were then loaded directly to a precasted gel that 
contained a separation gradient of 10-15%. The gel was then applied to the Pharmacia 
PhastSystem ™ which is a semi-automated electrophoresis apparatus. 
For visualization of the sample under study, the gel obtained after a typical run 
was stained for about 1 hr (solution of 0.1% Coomassie brilliant blue R, 30% methanl, 
10% acetic acid), and then destained overnight (solution of 30% methanol, 10% acetic 
acid) and then the gels were placed in a preservation solution (5% glycerol, 10% acetic 
acid) for 1 hr.  
REMOVAL OF ACTIVATI!G METALS FROM BUFFERS A!D 
PLASTICWARE 
 
The protein samples required to remain in metal-free status were stored and 
handled in plasticware using buffers that had been previously de-metalated. In order for 
this to occur, the plasticware was soaked in a solution containing 10% nitric acid for 
about 15-20 minutes. The plasticware was then washed in Chelex treated Milli-Q water. 
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In order to remove divalent metals from all buffers and Milli-Q water, these 
solutions were applied to a Chelex 100 resin using a peristaltic pump obtained from 
Pharmacia.   
PREPARATIO! OF PROTEI!S FOR ELECTROSPRAY MASS 
SPECTROMETRY  
 
The molecular mass for all proteins purified was determined using electrospray 
ionization mass spectrometry (ESMS). Samples in storage buffer were first exchanged 
into Milli-Q water and introduced into a Micromass Q-TOF Global Ultima mass 
spectrometer using an eluant of 50:50 H20: acetonitrile plus 0.2% formic acid. These 
samples were then run in positive ion mode and m/z ratios were deconvoluted using the 
MaxEntl algorithm in the MassLynx (V4.0, Micromass Limited/Waters Milford, MA) 
software provided by the manufacturer.  
DISULPHIDE REDUCTIO! 
 
Glutathione (GSH) is available in the reduced form and obtained from Sigma. 
Therefore no reduction was necessary. Gspd and T(SH)2 however, are commercially 
available as peptide disulfides from Bachem. Both thiol disulfides were reduced using the 
TCEP immobilized reducing gel obtained from Pierce. TCEP was chosen as the reducing 
agent as it is a rapid reducer and is slow to oxidize in air (170) and is essentially 
irreversible (171) when compared to its reduction counterparts such as DTT (170) 
especially at pH values below 8 (172). Also unlike oxidized DTT, oxidized TCEP will 
not directly catalyze thiol-disulfide exchange reactions (171). These conditions are 
optimized when the pH is lower than 7.6 which is the pKa of the phosphonium centre. 
TCEP was also unstable in phosphate buffer especially between pH 7 and 8. Tests on the 
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stability of TCEP in various buffers indicated that it was very stable in HEPES (170) and 




























Scheme 12. Method of Thiol reduction using TCEP 
Considering these reduction conditions immobilized TCEP disulfide reducing gel was 
used with a reduction capacity of 8 µmol/mL gel obtained from Pierce and was always 
present at two times the concentration needed for reduction to occur.  
The sample for analysis was weighed in the 4-8 mg range which required 
approximately 2.5-6 mLs of gel slurry which theoretically contained 50% Milli-Q water. 
This gel slurry was first spun at 5800 rpm in a VWR Clinical 100 ™ centrifuge at 4 ˚C 
for 2 minutes each time, to exchange the water for 500 mM chelex treated Hepes buffer 
which was sparged with argon. In between spins and discarding of the supernatant the 
beads were washed with sample buffer by vortexing using Fisher Vortex Genie 2™ at 
setting 3 until the beads were completely resuspended.  
This buffer was also used to dissolve the disulfide to a 500 µL sample solution 
regardless of concentration. This solution was added to the gel in such a way as to 
achieve a maximum of 2 mLs of reduced thiol. The sample and gel solutions were then 
incubated (stirring) according to manufactures specifications (approximately 1 hr for the 
aforementioned sample weight) at room temperature under argon. 
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The resulting reduced thiol was harvested by centrifugation on 5800 g at 
approximately 10 ˚C for 15 minutes. The resulting solution was then resuspended by slow 
pipetting and then placed in a column. The solution was then separated from the beads 
using the column method (described by manufacturer) under argon at all possible times. 
This recovered thiol solution was immediately titrated with 0.1 M HCl until pH 7 was 
achieved. This resulting solution was stored overnight at -20 ˚C. 
THIOL CALIBRATIO! 
 
Accurate concentration determination of thiols are pertinent due to the high cost 
of these precious thiol co-substrates and precise make up of substrate concentration for 
assay analysis. Therefore Ellman’s reagent was used to determine the concentration of 
the reduced thiols recovered from solution (174). The reagent for quantification is 5’,5’-
dithiobis-(2-nitrobenzoic acid) (DTNB) which reacts with thiolate anions in a thiol-
disulfide  exchange reaction in order to generate a chromogenic product 2-nitro-5-












Scheme 13. Reaction of DTNB liberating colored product NTB 
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There are a few concerns that were considered in order to create a protocol for 
thiol determination. The reaction has a pH dependence requiring a pH > 7 in order for 
deprotonation of the thiol proton so that the reaction may take place (176). In addition to 
this, if it is done at low pH values then there will be a lack of absorbance of the 
protonated NTB which has a pKa value of 4.5 (177). Even if the pH is neutral, especially 
in the presence of redox active species, then unwanted side reactions could occur such as 
alkylation and oxidation reactions which leads to varying background absorbance over 
time. The most detrimental drawback of the assay protocol as previously described is the 
limited sensitivity with a detection limit of approximately 3 µM which would be 
unsuitable for samples with low concentrations (175). Another thing to note on the 
sensitivity of the assay is that NTB is sensitive to light. The liberated NTB anion seems 
to undergo photochemical conversion to the nonchromophoric derivative DTNB (178).  
With these considerations in mind, thiols were quantitated in 100 mM 
potassium phosphate buffer at pH 8. This buffer was first degassed and sparged with 
argon before the introduction of the thiol samples. The recovered thiol samples were then 
diluted approximately 500-fold and then to this solution DTNB was added in at least a 5 
fold in excess. The reaction vials were inverted and the reaction allowed to proceed for 
approximately 20 minutes in the dark. Detection of the liberated NTB anion observed at 
412 nm. Then the calculations used to quantity the amount of free thiol available for the 
reaction to occur utilized the extinction coefficient of 14140 M-1cm-1 (179). 
E!ZYME KI!ETICS 
 
The enzyme assays were done as documented by Azira et al. (155) but the assay 
concentrations were obtained as previously documented by Clugston et al. (61) . 
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Solutions of the hemithioacetal substrate at given concentrations were obtained by 
incubation of various concentrations of the thiol and MG in 100 mM potassium 
phosphate pH 7 buffer which was degassed then sparged with argon. This substrate 
solution was then allowed to equilibrate at room temperature for approximately 15 
minutes in order for non-enzymatic hemithioacetal formation to occur. 
Free thiol concentration was minimally maintained at 0.1 mM to circumvent 
enzyme inhibition (180). The hemithioacetal concentrations were then calculated using 
the dissociation constants for the species at pH 6.6 with Kdiss = 3.1 mM (167). The 
equilibrium equation used is as follows: 
Kdiss




GSHtotal GSHcomplex 0.1 mM
 
Figure 23. Method for calculation of substrate concentration in solution 
Kinetic measurements for enzyme activity were monitored 
spectrophotometrically at 240 nm observing the accumulation of S-D-lactoyl 
thiolconjugate in the case of GlxI (181) and its disappearance in the case of GlxII. These 
reactions were monitored using UVStar™ UV- Transparent Microplates (96-well flat 







KI!ETIC A!ALYSIS OF GLXI 
 
E!ZYME MOLECULAR WEIGHT VERIFICATIO! 
 
E. coli GlxI was purified to greater than 95% purity as shown in figure 10. The 
monomer shown through ESMS analysis indicated a protien of molecular mass14.7 kDa. 
The purification sample from approximately 5 g of cells gave a total yield of 












































































GLXI STA!DARD KI!ETICS 
 
Kinetic analysis was carried out determined using 8 substrate concentrations 
from 0.04-0.7 mM. These assays were performed in triplicate in separate experiments for 
reproducibility. The following data demonstrates the kinetic curves fit using the Grafit 
program to determine enzyme kinetics. In each of the kinetic experiments approximately 
3 nM GlxI enzyme was added to a microtiter well consisting of 200 µL total volume. The 
slope for kinetic competence was observed for up to approximately 300 seconds utilizing 
the line of best fit. 
 
 
Figure 25. Data curve fit of enzyme kinetics obtained for GspdSH (A) and T(SH)2 (B) respectfully using 
the GraFit program (182). 
 
The following table demonstrates the kinetic values obtained for Gspd and T(SH)2 GlxI 






















































































GSH 704 ± 0.4 61 ± 4 344 ± 8 56 100 
GspdSH 123 ± 6 204 ± 39 61 ± 3 3 5 
T(SH)2 47 ± 0.7 199 ± 25 24 ± 0 1.2 2 
 
KI!ETIC A!ALYSIS OF GLXII 
 
E!ZYME A!D MOLECULAR WEIGHT VERIFICATIO! 
 
The enzyme was verified to be a 28 kDa monomer has been previously 
determined (160) and was purified to greater than 90% as shown in the following figures. 
A batch of approximately 4.8g of cells per liter gave a sample of approximately 75mg of 
protein. 
50:50/MeCN:Water + 0.2% FA
mass











Figure 26. Molecular spectrum and SDS PAGE analysis for purified E. coli GlxII 
 
EVIDE!CE FOR KI!ETIC ACTIVITY OF GLXII 
 
Kinetic parameters for GlxII were determined using 8 substrate concentrations 
ranging from 0.04 mM to 1.0 mM monitoring a decrease in absorbance at 240 nm. At 











reading indicative of GlxII activity. The following figures displays the S-D-lactoyl 
conjugates of T(SH)2 and GspdSH being hydrolyzed to form the proposed D-lactate and 
regenerating the respective thiol conjugate. 
 





















Figure 27. Absorbance versus time plots of GlxII on GspdSH Substrate Conjugate 
 

























For substrate concentrations above 0.7 mM, results are thought to be unreliable 
for accurate kinetic data measurements due to the high absorbance of the thioester group 
of S-D-lactoylglutathione (183). This should be seriously considered in the other thiol 
conjugates due to the likeness in behavior thus far. Therefore, a more sensitive DTNB 
assay was used which would eliminate any rise in absorbance typically found around 240 
nm of proteins and nucleic acids (184). The DTNB assay was monitored at 412 nm. 
OPTIMIZATIO! OF THE DT!B ASSAY 
 
The assay was conducted with the natural substrate S-D-lactoylglutathione 
obtained from Sigma and with the substrate obtained from E. coli GlxI and then filtering 
the enzyme to obtain the solution. The assay was then performed varying the 
concentrations of DTNB (7.5 mM and 0.75 mM). In the latter case, a substrate 
concentration of 1 mM was first reacted with GlxI and monitored until baseline. This 
reaction occurred for approximately 1hr before the substrate started to degrade around 
4500 seconds. The enzyme was then removed from the solution using 3K nanosap 
obtained from Pall. DTNB was then added to the solutions obtained and monitored to 
baseline. This reaction occurred in approximately 5 minutes for both concentrations. It 
was then decided, that the DTNB concentration in each assay will be two times the 
concentration of hemithioacetal theoretically present in solution to account for the excess 
GSH that might be present in solution.  
Further verification was also needed to determine whether or not enzyme 
kinetics was affected by the use of DTNB and methanol in solution as methanol was used 
to obtain soluble DTNB. To carry out these experiments, enzyme kinetics was obtained 
using the substrate made from GlxI under the following three conditions: methanol and 
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no DTNB, methanol and DTNB, no methanol and no DTNB (control). There was no 
significant difference in the specific activities obtained using five substrate 
concentrations ranging from 0.05 mM to 0.5 mM. It could be concluded then that the use 
of methanol and DTNB does not significantly affect the assay results and the DTNB 
assay can be used to obtain enzyme kinetics. 
Studies in the Honek laboratory on GlxII enzymes obtained kinetic values 
monitoring the decrease in absorbance at 240 nm for the disappearance of S-D-
lacotylglutathione (160). S-D-lactoylglutathione was commercially available from Sigma. 
The substrates used in this assay for determination of the kinetic values of Km=184±22 
µM, Vmax = 112± 24 µmol/min/mg, kcat=53/s, kcat/Km = 4.7 x105/M/s with the 
addition of 5 µg of protein per mL.  
The assay was performed using the method reported by O’Young and co-
workers with some alterations for DTNB sensitivity by utilizing 100 mM potassium 
phosphate buffer pH 8.0. The commercially available S-D-lactoylglutathione was used, 
however these kinetic values were not consistent with the kinetic values obtained using 
the S-D-lactoylglutahione substrate made from E. coli GlxI.  
To correct for this error the assay was repeated, this time using the endpoint 
reading of the S-D-lactoylglutathione obtained from commercially available material to 
determine the actual concentration of S-D-lactoylglutathione present in solution. The data 
indicated that 37.6% of the theoretical substrate concentration was present in solution; the 
concentrations assayed had less than a third lower than expected when calculating the 
enzyme kinetics. This could resolve the discrepancy obtained when using both substrates 
(commercial versus prepared). 
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Previous scientists indicated that no inhibition of GlxII activity was detected 
when 0.2 mM DTNB (185) or even with 10 mM DTNB (80) was added to the solution in 
their respective studies. These researchers performed this assay using 0.75 mM DTNB in 
cell free extracts rather than with the purified enzyme to obtain kinetics, therefore an 
appropriate concentration of DTNB should be found to assay in this experiment. 
The assay was replicated using the natural substrate, however when reduction of 
the thiols took place it was difficult to retain enough substrate to assay for GlxII activity. 
To correct this issue previous authors performed the same assay with L. major GlxII by 
adding DTT in the buffer to reduce the disulfide and produce the thiol conjugates (162). 
GLXII STA!DARD KI!ETICS 
 
The assay was therefore carried out as follows. The GlxI hemithioacetal 
substrate concentration was made up to greater than 2 mM and then assayed with GlxI for 
1 hr at room temperature. The GlxI enzyme was then separated from this solution using a 
3 kDa cut off membrane. The flow through was then harvested and measured for 
endpoint reading at 240 nm to quantitate the amount of GlxII substrate present. To this 
solution DTT was added such that there were 3.5 mM DTT for every 1 mM GlxII 
substrate. After DTT was added the solution was then incubated in the dark for 20 
minutes. These solutions were then diluted to the appropriate substrate concentrations and 
assayed for GlxII activity.  
At high concentrations, there is a marked decrease in absorbance occurring at 
240 nm indicating that GlxII in fact hydrolyses this substrate. Under these assay 
conditions, the absorbance obtained is too high to be read by the spectrophotometer due 
to the excess reduced thiol in solution as well as the presence of a side reaction between 
  
 90 
DTT and DTNB. The assay concentrations used for analysis were 20 - 100 µM. Standard 
kinetic values were obtained using Lineweaver-Burk plots as can be seen in the following 
diagrams with the kinetic parameters tabulated.  
 
Action of GlxII on S -D-lactoyl Conjugate of T(SH)2 






































Figure 29. Lineweaver-Burk plot of GlxII activity with the S-D-lactoylconjugate of T(SH)2 
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Action of GlxII on S -D-lactoyl conjugate of GspdSH



































Figure 30 Lineweaver-Burk plot of GlxII activity with the S-D-lactoylconjugate of GspdSH 












GSH 112 ± 24 184 ±22 61 331522 100 
 
GspdSH 2.6 ± 0.03 45 ± 0.1 58 ± 0.7 1289 X 103 0.03 
 
T(SH)2 29 ± 1 415 ± 11 70 ± 1 169 X 10
3  <<1 
 
 
VERIFICATIO! OF D-LACTATE USI!G D- A!D L-LACTATE 
DEHYDROGE!ASE 
 
The enzymes D-lactate dehydrogenase (D-LDH,EC. 1.1.1.28 ) and L-lactate 
dehydrogenase (L-LDH,EC 1.1.1.27) were employed to determine the detection of D-
lactate formation in solution after the application of E. coli GlxII. D-LDH catalyzed the 
NAD-dependent conversion of pyruvate to the D-isomer of lactic acid. This reaction is 
reversible and the forward reaction (pyruvate conversion) occurs with a maximum rate at 
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pH 7.5. The reverse reaction where D-lactate is oxidized occurs at a pH optimum of 8.0 
(186). The reaction leading to the enantiomer L-lactic acid is catalyzed by another 
enzyme L-LDH. From the sequence alignment, L-LDH and D-LDH belong to two distinct 









Scheme 14. Reversible inter-conversion of pyruvate to D-Lactate catalyzed by D-LDH (190) 
 
In order to determine whether the Gspd and T(SH)2 thiol conjugates produced 
D-lactate in solution the assay was performed according to Irsch and collegues (159). This 
was done in 100 mM Tris pH 8.5 with 5 mM NAD+ with the addition of approximately 
2.75 units of each enzyme (L-LDH or D-LDH) solutions to the assay. The separate 
reactions were allowed to take place for 1 hr until equilibrium was reached and then 
endpoint readings were taken to see the overall change in absorbance which was 
monitored at 340 nm at 25 ˚C with an extinction coefficient of 6.22 mM-1cm-1 (159, 191). 
An increase in absorbance was detected only in the solutions containing the D-LDH 








In a cellular system survival is pertinent and the bacteria may develop methods 
or systems in order to facilitate their continued existence. Evidently thiols play a key role 
in the survival of these organisms via many pathways. One such method is through the 
glyoxalase system, which has been previously described as a means of detoxifying MG 
where reactive α-oxoaldehydes such as MG can react with both proteins and nucleic acids 
and are considered to be mutagens (84-87, 104).  
To date, the hemithioacetal formed from GSH and MG has been the only 
substrate studied in the E. coli glyoxalase system. However other parasitic organisms 
such as the trypanosomes and leishmanias possess glyoxalase systems but their enzymes 
are known to utilize alternative thiols. T(SH)2 replaces GSH in the pathway and studies in 
this area could give specific information on the substrate binding in the active site as well 
as the substrate specificity of all of the prokaryotic enzymes. This study is particularly 
important in conjunction with other studies as there are more significant differences 





















between these prokaryotic enzymes and the human enzymes provide significant potential 
for inhibitor investigations (155). 
In addition to this, high stress conditions such as the late log growth phase of E. 
coli, significant amounts of GspdSH is manufactured by the organism and many 
scientists have been puzzled by this phenomenon (118). In addition to this, GspdSH has 
proved to be a viable substrate in the prokaryotic GlxI enzymes from the leishmanias and 
trypanosomes previously mentioned. This gives feasible reasons to suppose that if this 
occurs in E. coli GlxI the organism may be producing the thiol to deal with chemical 
stress as a means of detoxifying the cell of molecules such as MG.  
These results obtained coupled with previous studies where GspdSH is 
produced more rapidly show that this manufacture of GspdSH is an important component 
in the assistance with enzyme detoxification. The catalytic efficiency (kcat/Km) of the E. 
coli GlxI enzyme with GspdSH and T(SH)2 is approximately 5% and 2% respectfully 
when compared with its natural hemithioacetal substrate of GSH which shows that unlike 
GlxI from L. infantum the E. coli enzyme is significantly more specific towards GSH and 
yet more versatile than the trypanosomes and leishmanias discussed previously. The 
enzyme’s efficiency in the presence of either of the tested substrates display that E. coli 
GlxI is able to utilize GspdSH and (TSH)2 although not very well. This also confirms 
earlier predictions that the active site of the E. coli enzyme is large enough to facilitate 
substrate binding of the flexible spermidine molecule as well as the larger T(SH)2 
hemithioacetal (64, 153, 155).   
In the second step of the glyoxalase reaction, the thioester product is hydrolyzed 
to produce D-lactate and regenerate the thiol cofactor GSH. In the trypanosomes this 
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occurs with both GspdSH and T(SH)2 thioesters with much more affinity of the enzymes 
with respect to GspdSH. These findings are consistent with cell growth conditions where 
the late log phase of the enzyme is under higher stress conditions and therefore the 
enzyme must also utilize this thiol. Findings in the Honek lab utilizing E. coli GlxII 
indicate that GspdSH thioester and the T(SH)2 thioester are used by GlxII. 
The thiol co-substrates GspdSH and T(SH)2, are both utilized as substrates for 
GlxI and as a result GlxII producing the D- instead of L-lactate product. The results are 
consistent with those of the aforementioned enzymes from the leishmania, human, and 
trypanosomal organisms, as the presence of D-lactate indicates that these thiols function 
in E. coli performing in such a way as would a true glyoxalase system (87, 118, 150, 
151).  
This study will greatly benefit inhibitor design studies for the trypanosomatids 
as it gives an idea of how these thiol molecules react in the active site with not only 
trypanosomes but the bacterial counterpart E. coli which proves to be a very versatile 





CHAPTER 3: PUTATIVE FOSFOMYCI! RESISTA!CE I! 
E56A GLXI 
 
I!TRODUCTIO! TO THE VICI!AL OXYGE! CHELATE 
SUPERFAMILY 
 
Evolution of protein structure is the essence behind an enzyme’s functions and 
processes and understanding this aspect would enrich the scientific community in 
learning how to predict protein behaviour. This could have many applications in drug 
development and is important in structural genomics research which can then give an 
idea of the process of evolutionary diversification of enzymatic catalysis (54). 
Scientists have accepted that proteins may be grouped or classified into 
superfamilies which may be detected through pairwise or multiple sequence alignments 
and even better through similarities in their three dimensional structures (54). When 
grouped, these proteins may contain a series of conserved residues that may define a 
relationship in the protein structure and function (192, 193).  
In some cases, the type of reactions among members of a superfamily, may 
differ but mechanism is related through the intermediate stabilized in the enzyme active 
site. One example is the enolase superfamily, which differ in functionality such that these 
enzymes perform racemizations, epimerizations, and β-eliminations but they are all 
obligated to form an enolic intermediate. These enzymes have a similar structure, notably 
a TIM barrel that is preceeded by a β3α4 domain (192, 194). This aspect indicates that 
members of a particular superfamily usually share some structural commonalities and it 
could be supposed that from the mechanistic similarities these proteins could have been a 
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result of divergent evolution from a common ancestor. This could be responsible for their 
functional diversification (54). 
The above example does not apply to all superfamilies, as there are instances in 
metalloenzyme superfamilies where members catalyze very different reaction sets with 
diverse intermediate formations which may be unrelated (195). This phenomenon is 
exemplified by the members of the vicinal oxygen chelate superfamily (VOC). 
MEMBERS OF THE VICI!AL OXYGE! CHELATE SUPERFAMILY 
 
These member proteins are structurally related and they provide a catalytic 
metal center that may possess one to three readily accessible metal coordination sites that 
promote a direct electrophilic participation of the active site metal during catalysis (53). 
Scientists also believe that these metals may have played a significant part in the 
evolution of protein folding (53). Analyzing the sequence alignments, three-dimensional 
structures, and functionalities of these proteins indicates that there are at least five distinct 
members of the VOC superfamily. 
Table 7. Functionally distinct members of the VOC superfamily 
Member Metal Ion Reaction Type 
BRP None None, Sequestration 
FosA Mn2+, Mg2+ Nucleophilic epoxide ring opening 
Extradiol Dioxygenases Fe2+, Mn2+ Oxidative cleavage of C-C bond 
GlxI Zn2+, Ni2+ Isomerization 




Originally the family was analyzed mechanistically utilizing the fosfomycin 
resistance protein (FosA) which was found to be a Mn2+ dependent enzyme with regions 
of the sequence similar to the glyoxalase I (GlxI) enzyme and the extradiol dioxygenases 
(195). The members of the VOC received the name based on the hypothesis that there is 
an inner sphere coordination of substrates or intermediates to the metal centre via vicinal 
oxygen ligands (192, 196). The methylmalonyl-CoA epimerase (MCEE) is another 
enzyme thought to be a member of the VOC superfamily (197) as well as the bleomycin 
resistance proteins (BRP) (198). In the case of the MCEE, it has mechanistic similarity 
but does not function by the chelation of vicinal oxygen ligands (54). The BRP does not 
even function as an enzyme and contains no metal centre but possesses a hydrophobic 
cavity thought to have been occupied by metal in its progenitors that bind the antibiotic.                   
Figure 32. Examples of the alternate arrangements of the metal binding sites composed of paired 
βαβββ motifs in the VOC superfamily. (A) human GlxI dimer, (B) domain-swapped GlxI monomer 







EVOLUTIO! OF THE VOC SUPERFAMILY 
 
It has been proposed that the basis for evolution in the enzymes of the VOC 
superfamily involve gene duplication, fusion, and single modification. Gene duplication 
for example is recognized as the primary mechanism where new functions are organized 
during the course of evolution (53). Evidence have been raised where proteins have 
received the duplication especially among members of superfamilies (53). 
Examining Figure 31, the progenitor of the superfamily is thought to be a 
minigene-encoded single βαβββ motif. A simple dimer is thought to arise based on the 
symmetry of the metalloprotein dimer, but further proposals suggest that gene duplication 
or gene fusion would lead to a more robust two-motif pseudosymmetric metallomonomer 
and enhance the dimer interaction (54). Further rearrangement could have occurred from 
a bidentate chelate to a tetradentate system that could facilitate the enzyme’s function 
with lower metal ion concentrations. Then additional gene duplication-fusion events 
could give four motif monomers an arrangement which is observed in the extradiol 
dioxygenases (54), and in yeast GlxI (199). 
Further possibilities leading to a more enhanced enzyme with respect to 
stability, and even new catalytic properties could be as a result of three dimensional 
domain swapping and continued gene duplications.  One suggestion would be if one of 
the four ligands are lost about the metal centre such that diversification of that enzyme 




Determining which enzyme first appeared is a very difficult task, however; 
scientists have managed to argue that the enzymes with four protein ligand geometry 
such as GlxI and MMCE may have been around before FosA and the extradiol 
dioxegenases which are tridentate systems catalyzing more complex bisubstrate reactions 
(54). However this is thought to be a large evolutionary step and therefore it may be more 
practical to believe that small evolutionary steps could have occurred to make up this 
process. One particular example is the protein FosB. It was studied and isolated from 
Bacillus subtilis and is found to be a homologue of FosA. What is interesting about this 
particular protein is that this Gram-positive bacterium does not biosynthesize GSH. This 
protein acts as a thiol transferase enzyme that catalyzes the Mg2+ catalyzed addition of L-
cysteine to the epoxide ring of fosfomycin therefore conferring resistance to the antibiotic 
(54). Enzymatic activity for FosB is so low that it is thought to be a precursor for the 
more efficient FosA enzyme. 
The last member that warrants mention is the BRP as it neither catalyzes a 
reaction nor contains a metal center. If in the early stages of evolution of the VOC 
superfamily there was optimization of an emergent metal binding motif, then the BRP 
would be the perfect candidate that displays a situation where the metal binding 
capabilities of the progenitors had been atrophied in order to develop a protein that would 
be suitable for just sequestering the antibiotic (53). This hypothesis is sound as the loss of 
function of one protein to make way for another is not unusual (54). This could also 
explain the emergence of newly resistant bacteria and create insight in the field of 





Figure 33. The proposed evolutionary pathway for the VOC superfamily (53, 54).  
 
STRUCTURE: THE VICI!AL OXYGE! CHELATE SUPERFAMILY  
 
Fundamentally, the structure of the subunit in the VOC superfamily is described 
as a βαβββ motif which was first described in relation to the BRP (198). It is a 
homodimer where each subunit consists of two tandem motifs where the dimer is formed 
at the interface by an edge to edge interaction of one subunit with the other. This motif is 
very similar among the VOC enzymes such as in the human or E. coli GlxI which require 
dimerization for catalysis to occur with the exception of Pseudomonas putida GlxI from 
which is active as a dimer or a monomer (200). In the general structure for the 
metalloproteins of the VOC superfamily there are usually four metal ligands two from 
each subunit of the enzyme. In the extradiol dioxygenases one of the ligands is absent and 
this is also true for Fos A. The residue E99 in the human enzyme is substituted with an 
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alanine in the extradiol dioxygenase. This opens up the enzyme for substrate binding as a 
solvent-occupied coordination site is formed (54). 
MECHA!ISTIC RELATIO!SHIPS OF THE VOC SUPERFAMILY 
 
These family members catalyze a series of diverse reactions. However, as 
aforementioned these reactions share some commonality in the enzymes in that they all 
require metal for catalysis with the exception of the BRP. Designating this family a VOC 
derives from the hypothesis that the transition states for the reactions will benefit from 
inner sphere coordination of vicinal oxygen atoms of the substrate or the intermediate to 
the metal site with the exception of MCEE (54). Nevertheless all of the enzymes benefit 
from the electrophilic assistance available from the metal centre. The enzyme GlxI is the 
member that most suits the VOC terminology (54). 
MCEE contains a Co2+ metal center (201). The E. coli GlxI is also found to be 
activated by Co2+ even though the enzyme is maximally actived by Ni2+ (64). Like GlxI, 
the catalyzed reaction is an isomerisation reaction involving an enolic intermediate. The 

























































Figure 34. Mechanistic similarities with two members of the VOC superfamily. A) H. sapiens GlxI 












                       
                         (A)                                                                                  (B)                          
 
                                                                        (C) 
Figure 35. Crystal structure representations of some members of the VOC superfamily. 
(A) Cartoon of BRP from Streptoalloteichus hindustanus with G18E, D32V, L63Q, G98V mutations 
that enhance thermal stability of the protein (202). (B) Shows DHBD from Burkholderia cepacia 
(203), and (C) is a representation of GlxI from E. coli (64). The metal atoms are drawn as spheres 
and the dimers can be seen colored by their secondary structures showing βαβββ structural topology 
similarities among the enzymes.  
 
Analysis of the mechanism led scientists to suggest that the two glutamate 
residues present in the active site disengage from the metal ion and one may act as a base 
to abstract a proton for the substrate; the same may occur in GlxI with Glu-172 acting as 
the potential base (59). 
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I!TRODUCTIO! TO THE FOSFOMYCI! RESISTA!CE PROTEI!S  
 
It is clear then that mechanistically speaking, several members of the VOC 
family can catalyze similar reactions. Turning the focus to another member: FosA, the 
enzyme catalyzes another type of reaction but utilizes the cofactor GSH which is also 
present as a cosubstrate for GlxI (54, 55, 200). FosA supports a nucleophilic addition of 
GSH to the C1 of the oxirane ring of the antibiotic fosfomycin (195, 204). Fos A has 
been found to be optimally active in the presence of both Mn2+ and K+ and is thought to 































Scheme 15. Overview of the mechanisms of fosfomycin resistance proteins (205) 
The other fosfomycin resistance proteins that have been discovered are coined 
FosB and FosX (206). The former is a Mg2+ dependent enzyme thiol transferase and the 
latter catalyzes the hydrolysis of the oxirane ring in the presence of Mn2+ (206). When 
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analyzing the sequence alignment among the Fos proteins, these subfamilies of enzymes 
share a 35% sequence identity in several microorganisms including Mesorhizobium loti 
and the pathogens Listeria monocytogenes, Brucella melitensis, and Clostridium 
botulinum (206). Based on these sequence alignments three important residues are 
conserved in the active site: H-7, H-69, and E-118 (207). 
In the following table the catalytic properties of the Fos enzymes can be seen. 
FosA and FosX produce robust resistance to fosfomycin in P. aeruginosa and L. 
monocytogenes respectively. FosB also produces cellular resistance but not as well as the 
other enzymes and does utilize GSH as a substrate to a much lesser extent that its natural 
substrate (197).  
Table 8. Catalytic Properties of  Fos Enzymes (197). 






) Km (mM) 
FosA (197) GSH 98000±7600 610±67  
FosB (206) L-CysH 180±20 6.3±0.3 35±3 
 GSH 1.8±0.2 0.027±0.002 15±2 
FosX (207) M. loti 500±60 0.15±0.02  




Fosfomycin was first reported and characterized by scientists at Merck in 1969 
as a potent, broad spectrum antibiotic (1R,2S)-epoxypropylphosphonic acid 
(phosphomycin subsequently coined fosfomycin), which is synthesized by certain strains 
of Streptomyces (208, 209) and is effective against both Gram-negative and Gram-
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positive microorganisms (209). The function of the antibiotic is to inactivate irreversibly 
the enzyme catalyzing the first committed step in peptidoglyan biosynthesis, 
UDPGlcNAc-3-enolpyruvyltransferase (uridine-5’-diphospho-N-acetyl-D-glucosamine 
(UDPGlcNAc), MurA) (195). Upon analysis of the inactivated enzyme, the antibiotic was 
found to have alkylated a cysteine residue (210) Cys-115 located in the active site (211). 
In microbiological studies acquired immunity to this antibiotic has been observed very 
early and the resistance is associated with mutations in the genes that affect the transport 
of the antibiotic to the cytosol of the cell (212, 213) and also with mutation in the actual 














Inactive MurA  




In 1982, scientists identified a plasmid from clinical isolates that also conferred 
resistance to fosfomycin (215). Further investigation established that there was a gene 
encoding a 16 kDa protein that catalyzed the addition of GSH to the antibiotic and this 
protein was coined FosA (204, 216). 
The crystal structure of FosA from Pseudomonas aeruginosa has been solved 
(217). The protein appears to be very similar to that of GlxI as the metal sites exhibit a 
domain swapping arrangement where one motif derived from each subunit. There is 
however, a more interesting feature when comparing the two enzymes in that the β-2 
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strand of the second βαβββ motif is truncated and this arrangement aids the binding of a 
K+ ion which is located in a loop between the second and third β strands. There is a 
significant part of the dimer interface that includes an α-helix located near the C-teminus 
is in close contact with the 3-terminal βαβββ motif from the opposite subunit. In addition 
to this, there is also a short C-terminal β-strand that seems to interact with the second β-
strand from the aforementioned N-terminal motif (217). 
There are a few conserved residues that are located within hydrogen bonding 
distance of the phosphonate oxygens 4.4 Å away from the K+ ion. These residues are 
Arg-119, K-90, and Y-100. The backside of the C1 carbon in the oxirane ring to which 
the GSH is added is located at the surface of the protein near a short solvent channel. 
There is still more information required to determine the residues responsible for GSH 
binding (217).  
FOSA METAL BI!DI!G A!D ACIVITY 
 
FosA is a manganese-activated metalloenzyme that inactivates the antibiotic 
fosfomycin by adding GSH to the C1 carbon of the epoxide ring as shown in Scheme 1.  
FosA is a plasmid-encoded protein that was first identified in clinical studies of microbial 
populations resistant to the antibiotic (218). This enzyme requires Mn2+ for maximum 
catalysis and also requires the presence of K+ for optimal catalytic activity (197). 
Sequence alignment of Fos A with other members of the superfamily such as 
Fos B, GlxI, and DHBD suggests that the metal binding sites are His-7, His-66, Glu-110 
with three water molecules coordinating to the metal which was thought to complete an 
octahedral geometry in the active site (197). These results were also confirmed by 
analysis of the crystal structure of the P. aeruginosa with the exception of metal 
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coordination at the active site. Mn 2+ is coordinated by four protein ligands in a highly 
distored tetrahedral geometry and a phosphate oxygen completes the inner-coordination 
sphere (217). Single mutation experiments involving these residues are consistent with 
confirmation of the ligands and with the sequence alignment predictions. The mutants 
alter the metal binding characteristics of the enzyme over a range of 104 and similarly the 
catalytic efficiency of the enzymes (197).  
The catalytic efficiency of FosA is high especially since the oxirane ring is 
highly unstable. Investigators found the turnover number of the enzyme with saturating 
substrate concentrations to be 1000 s-1 and the kcat/Km is within a factor of 10 of the 
generally accepted diffusion limits of 108 M-1s-1 (197). These scientists suggest that the 
enzyme has evolved to near maximum efficiency. The rate, is not however limited by the 
diffusion of the substrate but rather by the ligand exchange kinetics in the coordination 
sphere of the metal (197). 
                          20                    40      
FosX   MISGLSHITL IVKDLNKTTT FLEEIFDAEE IYSSGDDTFS   40 
GlxI   M--RLLHTML RVGDLQRSID FYTKVLGMKL LRTSENPEYK   38 
FosA   MLTGLNHLTL AVADLPASIA FYRDLLGFRL -------EAR   33 
 
                          60                    80      
FosX   LSKEKFFLIA GLWICIMEGE SLQERTYN-- ----------   68 
GlxI   YS------LA FVGYGPETEE AVIELTYNWG VDKYELGTAY   72 
FosA   WDQGAYLELG SLWLCLSR-- ---EPQYGGP AADYT-----   63 
 
                         100                   120      
FosX   -HIAFQIQAE EMDEYIERIK SLGMEIKPER SRVKGEGRSV  107 
GlxI   GHIALSV--D NAAEACEKIR QNGGNVTREA GPVKGGTTVI  110 
FosA   -HYAFGIAAA DFARFAAQLR AHGV---REW KQNRSEGDSF   99 
 
                         140                         
FosX   YFY-DYDNHL FELHAGTLEE RL-------- --KRYHK  133 
GlxI   AFVEDPDGYK IEL----IEE KDA------- -GRGLGN  135 
FosA   YFL-DPDGHR LEAHVGDLRS RLAACRQAPY AGMRFAD  135 
 
Figure 36. Sequence comparison of FosX from Listeria innocua (accession number Q92AV8), GlxI 




Experimental evidence suggests that the metal ion acts as an electrophillic 
catalyst for activation of the fosfomycin epoxide oxygen toward nucleophilic attack (195, 
210). From electron spin and nuclear magnetic resonance experiments, it is suggested that 
each subunit contains one metal ion binding in the active site and upon binding of 
fosfomycin and the product 1-(S-glutathionyl)-2-hydroxypropylphosphonic acid (GS-
fos), the coordination enviromnemt of the metal is altered, this is not the case when GSH 
is present (195).  
K
+
 BI!DI!G A!D CATALYTIC ROLE  
 
The K+ binding site is located in an extended loop between two β-strands and it 
is six-coordinate with four carbonyl oxygens and two serine hydroxyl groups that serve 
as ligands. There are no carboxylate ligands which might have been expected since it has 
been observed in many other proteins that bind K+. This absence should promote the 
electrostatic influence of the K+ ion in the active site since there are no counter balancing 
negative charges to the K+. The K+ is located 6.5Å from the Mn2+ ion, 4.4Å from the 
carboxylate of Glu-110, and 3.7Å away from the nearest phosphate oxygen (217). 
Electron paramagnetic resonance (EPR) spectrum analysis suggested that K+ is 
involved in the catalytic mechanism where there is a specific binding site in the enzyme-
substrate complex for K+ and may be directly interacting with the active site. There are 
three main observations to support this theory. There is firstly a pronounced effect of K+ 
on the EPR spectrum of the enzyme-Mn2+-fos complex, where increased anisotropy in 
the spectrum directly indicates that there is a distorted ligand field about the metal when 
it is in the presence of K+. Secondly, there is no alteration in the EPR spectrum when K+ 
is present in the absence of fosfomycin and the activation constant for K+ is sensitive to 
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any alterations that occur in the structure of the metal ion binding site. There is also high 
basal activity in the absence of K+ activation of the E113Q mutant suggesting that the 
carboxylate of Glu-113 is involved in the activation process directly (197). 
The substrate-bound structure supports this hypothesis as the coordinate 
geometry can be thought of as being trigonal bipyramidal where the two histidines and 
one phosphate oxygen occupy the coplanar equatorial sites and the carboxylate of the E-
110 then occupies one of the apical sites. The oxirane oxygen of the substrate, it is 
located at the other apical site. The K+ is 4.4 Å away from the nearest phosphate oxygen 
and may thus act in orienting the substrate. The hydroxyl group of S-94, which is found 
inside the K+ loop, forms a bridge between K+ and one other of the phosphonate oxygens. 
POSSIBLE CATALYTIC MECHA!ISM FOR FOSA 
 
The profound effect of fosfomycin on the EPR spectrum of Mn2+ bound to the 
enzyme in the presence and absence of GSH coupled with the effect of K+ during 
catalysis led authors to propose a method of catalysis that involves both monovalent and 
divalent cations. In this hypothesis, the transition state for the reaction of GSH with the 
ternary complex would involve an approach of a second anion (GS-) to the metal site.  
The x-ray structure (217) has provided insights into the mechanism. There are 
potential sources of electrophilic catalysis in the active site used to open the oxirane ring. 
In Scheme 3., the close proximity of the ring to the metal would suggest that Mn2+ serves 
to stabilize the alkoxide in a transition state and perhaps via a true trigonal bipyrimidal 
complex (217). The oxirane ring opening is accomplished by just the metal acting 
directly by protonation of the oxirane ring by a metal bound water molecule (219) or 
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from the hydroxyl group of Thr-9 which is conserved in the sequences of the plasmid-
encoded enzymes (217). 
    
                                     (A)                                                                        (B) 
Figure 37. Crystal structure displaying overall protein structure of FosA with metals bound (A) and 
detailed active site structure displaying the bound substrate (B) PDB 1LQP (217). 
 
 In both scenarios the K+ ion would serve to neutralize the developing charge in 
the transition state indirectly, as it would preserve a neutral or low charge in the active 
site during catalysis. This hypothesis is further supported in that the influence of K+ could 
be relayed through the hydroxyl group of Ser-98 within hydrogen bonding distance of 
Glu-110. The electrophilicity of the metal center would then be enhanced by the presence 
of K+; this would facilitate the delocalization of charge in the transition state directly (A) 
or through intervening water molecules (B). The proposed schemes are not correct in 
every detail but do display the role of K+ in the active site and further studies will 




















































Scheme 17. Proposed reaction mechanism of FosA (54). 
 
FOSX IS EVOLUTIO!ARILY RELATED TO FOSA A!D GLXI 
 
FosX is a new class of fosfomycin resistance protein that catalyzes the 
hydration of fosfomycin generating the vicinal diol. Genes encoding these FosX 
homologues have been found in many bacteria such as Clostridium botulinum, Brucella 
melitensis and Listeria monocytogenes which are all harmful pathogens (205). Scientists 
have demonstrated that FosX is regiospecific in its addition of a solvent derived oxygen 
molecule to the C1 carbon of fosfomycin (207).  
In L. monocytogenes, FosX  is 133 amino acids in length with a molecular 
weighed of approximately 16 kDa. This is a homodimeric enzyme that possesses a 
domain swapping arrangement where His-7 of one subunit joins His-69 and E-118 from 
 
 114 
the opposite subunit to form the divalent metal binding site. The average metal-ligand 
distances are 2.3 Å for His-7, 2.4 Å for H-69, 2.2 Å E-118 and the sulphate oxygen is 
approximately 2.8 Å away (205). The metal binding active site is cup shaped and is 
formed by paired βαβββ motifs that can be observed in other fosfomycin resistance 
protein members and members of the VOC superfamily (53, 54). 
There is a unique tail found in this protein that is not present in other FosX 
enzymes elucidated thus far. The confirmation of the tail is not consistent with catalytic 
activity from the crystal structure but there are certain interactions that should be called to 
attention. The C-terminal tail is usually a α-helix that extends away from the active site 
but in this case the tail loops back into the active site where a carboxylate oxygen from E-
126 is within hydrogen bonding distance of Thr-9 (205). This is most interesting as there 
is only one metal bound in FosX and if this enzyme is a precursor to FosA the 
confirmation and shape of this C-terminal arm could be promising in the development of 
a K+ binding site in order to make the protein more catalytically efficient. FosX is 
therefore more structurally similar to GlxI. 
 
IMPORTA!CE OF STUDYI!G FOSA A!D THE VOC SUPERFAMILY 
 
Remarkably this superfamily contains a wide range of chemical mechanisms to 
inactivate fosfomycin. This diversity is impressive and is clearly related to the metal 
centre in the active site. These centres are quite versatile as they may provide 
electrophilic assistance that are necessary with respect to redox chemistry. The overall 
βαβββ structural motif folds the protein in such a way as to maximize the catalytic 
versatility of the metal center to an extent that is not yet known (54).  
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Analysis of the sequence alignments of FosA with other enzymes of the 
superfamily shows great conservation of the metal binding residues. However, GlxI from 
E. coli contains only one bivalent metal (Ni2+) per monomer while fosfomycin contains 
both Mn2+ and K+ which may be involved in the catalytic activity. Interestingly there is 
another enzyme Fos X which is apart of the superfamily that hydrolyzes the antibiotic 
(205) with the use of one metal centre per subunit and displays close sequence similarity 
with E. coli GlxI. If FosA is a more evolved enzyme (197), it is probable that potential 
clues of this evolutionary process might be uncovered if E. coli GlxI could be mutated at 
the active site and then be able to confer resistance to the antibiotic. 
One of the most important reasons for studying this enzyme is that resulting 
information will benefit one’s knowledge of other enzymes that have similar 
characteristics to the structure of FosA even though the mechanisms or the superfamilies 
differ. As antibiotic resistance becomes more of a problem because of the use or overuse 
of “last resort” antibiotics (220), information on how antibiotic resistance occurs is vital 
to the scientific community. It is believed that antimicrobial resistance is often as a result 
of the selective pressure on microbes when the antibiotic is used. The three most common 
defences  against antibiotics include the alteration of the antibiotic transporter in the 
uptake of the drug, mutation of the antibiotic target, or even inactivation or sequestration 
of the antibiotic by a resistance protein (220). Fosfomycin resistance proteins are an 
attractive target as all of these defence mechanisms are thought to have occurred in the 






COMPARISO! OF FOSA A!D E. COLI GLXI ACTIVE SITES 
 
Since Fos A is thought of as the most catalytically efficient of all the Fos 
enzymes (197) it would be interesting to see what effect will GlxI have on fosfomycin 
resistance. In the absence of the FosA, E. coli is very sensitive to fosfomycin with a 
minimum inhibitory condition (MIC) of less than 0.025 mg/mL (207). Obvious 
differences in metal binding of FosA and GlxI exist, and the overall structural similarities 
of the enzymes that have been previously discussed. It is important to analyze the active 
sites of the proteins.  
To reiterate and focus on the Mn2+ binding site alone in the FosA enzyme, it is 
coordinated by three amino acids: His-7, His-64 and Glu-110 and a phosphate ligand 
(205). The GlxI Ni2+ metal binding site in the E. coli enzyme is coordinated by four 
amino acids: His-5, Glu-56, His-74, and Glu-122 (64). The glutamic acid presents a 
negative charge in the active site that if replaced with an amino acid of approximately 
neutral charge, will most likely mimic the ligand environment of the phosphate ligand in 
the active site. This could possibly allow the mutant GlxI to bind Mn2+. Studies show that 
GlxI is reactive to a much less extent with Mn2+ than it is with Ni2+ (62). In addition to 




                  
                                 (A)                                                                                  (B) 
Figure 38. Representations of the metal active site cavities of E. coli GlxI (PDB code: 1f9z) (64) and P. 
aeruginosa FosA (PDB code: 1LQK) (217). 
MATERIALS A!D METHODS 
 
PLASMID PURIFICATIO! A!D POLYMERASE CHAI! REACTIO!  
 
E. coli GlxI wild type plasmid DNA was first purified from MG1655/pGL10 
GlxI protein expression systems and then transformed into DH5α competent cells for 
DNA expression using the QIAprep® kit available from QIAGEN (221). The resultant 
plasmid DNA was harvested and used in the polymerase chain reaction (PCR). In order 
to obtain amplification of the desired mutant DNA, DNA polymerase, and desired 
primers were added to a reaction mixture (222) and placed in a temperature cycler. The 
optimal conditions for obtaining mutant DNA can be seen in the following table. 
Table 9. Conditions used for PCR analysis to obtain mutant D!A 
Segment Cycles Temperature (ºC) Time (s) 
1 1 95 30 
2 18 95 30 
  55 60 
  68 720 












Upon completion of this cycle the resultant solution underwent DNA digestion with the 
Dpn1 restriction enzyme to remove any of the original methylated DNA plasmid. This 
solution was then transformed into DH5α competent cells under three concentration 
dilutions: 1:80, 5:80 and 10:80 with the initial dilution being the most successful.  
PRIMER DESIG! 
 
Site directed mutagenesis was performed using the QuickChange® protocol 
(222). All oligonucleotide primers were prepared at Sigma.  
Forward Primer  
5’ ACC GAA GAA GCG GTG ATT GCC CTG ACC TAC ACC TGG GGC 3’ 
Reverse Primer 
5’ GCC CCA GTT GTA GGT CAG GGC AAT CAC CGC TTC TTC GGT 3’ 
MUTAGE!ESIS PROTOCOL 
 
The E56A point mutation was introduced using QuickChange® Site directed 
mutagenesis. This is a rapid four-step procedure that is used to generate a mutant with 
greater than 80% efficiency. Supercoiled double stranded-DNA containing the gene that 
codes for wild type GlxI was introduced to two oligonucleopeptide primers that contained 
the desired mutations. These primers were complementary to the opposite strands of the 
vector and were extended during temperature cycling (36).  
SEQUE!CI!G A!ALYSIS 
 
The purified DNA obtained from the DH5α competent strains were first 
subjected to concentration determination by spectrophotometric analysis at 260 nm. Then 
the sample was sent externally for sequencing.  The DNA sequencing was carried out by 
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a high quality capillary-based method utilizing the Applied Biosystems 3130xl Genetic 
Analyzer located at the University of Waterloo.  
 
DETERMI!ATIO! OF MI!IMUM I!HIBITORY CO!DITIO!S  
 
Minimum inhibitory conditions (MIC) for antibiotic potency evaluation are 
considered the ‘gold’ standard in determining the susceptibility of organisms to 
antibiotics or antimicrobial agents; it is used to judge all other methods of susceptibility 
determination (223). The MIC is defined as the lowest concentration of a drug tested that 
inhibits growth in an overnight culture (223, 224). There are organisms (usually 
anaerobes) that require longer incubation periods (223). It is necessary to note, that if the 
bacteria succumb to an antibiotic then the bacteria are susceptible. Intermediate resistance 
implies that the dose response is uncertain and sometimes for that microbe, higher 
concentrations of the antimicrobial agent are needed. Finally, resistance is described as 
robust viability of the bacteria in the presence of the antibiotic (225).  
In order to determine conditions to test for cell growth in vitro, the minimum 
inhibitory conditions tested for MG were based on studies determined by Kim and 
colleagues who screened for MG susceptibility (226) and also prior methods used in the 
Honek laboratory (unpublished data). Then four concentrations of MG: 0 , 5, 50 and 500 
mM were tested using the agar disk diffusion method (224). In reference to fosfomycin 
MIC concentrations pharmaceutical standards for testing fosfomycin activity have 
already been established by various organisations that determine clinical laboratory 
standards (225). The pharmaceutical concentrations in organisms such as E. coli, and 
Pseudomonas strains, in the presence of fosfomycin susceptible strains are those 
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concentrations less than 0.494 mM that inhibit cell turbidity and resistance is classified as 
persistent cell turbidity in concentrations greater than or equal to 0.988 mM (225).  
 
E56A PERFORMA!CE WITHI! CELLS 
 
Once the concentration range was determined for viability testing, test 
concentrations were determined by the universally accepted method of doubling dilution 
(223). These concentrations were then tested using the broth dilution method (224). 
Optical density readings were then taken at 600 nm every two hours over a twelve to 
fourteen hour period and then a final reading observed at the twenty-four hour mark. Ten 
culture tubes containing nine seperate antibiotic concentrations and a blank control 
solution were prepared in triplicate to a total final volume of 5 mL of all constituents in 
each tube. All test solutions contained 50 ug/mL of carbeniciilin. To the test 
concentrations, cells were added in a 1 in 100 dilution fashion therefore adding 5 µL if 
overnight culture to each of the culture tubes. The blank or reference concentration was 
LB containing 50 ug/mL of carbenicillin.  
These solutions were subjected to a time course assay in which the growth 
progression of the wild type versus mutant cells was determined. The assay was 
conducted over a 24 hr period in which absorbance readings were determined every two 
hours for 12 hours and then a final reading at 24 hours. The assay was performed three 
times for each of the test conditions.  
OPTIMIZATIO! OF PROTEI! EXPRESSIO! 
 
In order to optimize protein expression for the E56A mutant in E. coli 
MG1655 cells, a 5 mL starter culture containing 50 ug/mLampicillin was prepared 
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overnight in LB broth. To all test solutions the antibiotic carbenicillin was added to a 
final concentration of 50 ug/mL. Then a one in one hundred dilution was performed 
placing 50 µL of the starter culture into 50 mLs of LB in a 250 mL Erlenmeyer flask. 
This was performed under four test conditions and at temperatures of 25ºC and of 37ºC.  
Induction conditions were determined at two different cell concentrations with 
an optical density (OD) of 0.5 and 0.7. When the test solutions reached this optical 
density, four different concentrations of IPTG (0, 0.5, 0.7, 0.9 mM) were added to the 
flasks. These cells were allowed to grow for four and eight hours then overnight before 
samples were aliquoted and tested for protein expression using SDS-PAGE.  
PROTEI! PURIFICATIO! 
 
PROTEI! GROWTH A!D EXPRESSIO! 
 
After optimal protein expression was established, a E56A overnight starter 
culture was prepared and then transferred to a 1L flask containing LB. The cells were 
then permitted to grow until an OD of 0.7 was established in the flask. To this solution 
0.7 mM IPTG was then added and the cells were allowed to incubate for an additional 
eight hours.  
CELL HARVESTI!G A!D LYSIS CO!DITIO!S 
 
Cells were subjected to harvesting and lysis utilizing the same conditions as 
previously described for the isolation of wild type GlxI. Once the growth cycle was 
complete, cells were transferred into a JA-10 rotor with a speed of 6000 rpm for 15-30 
minutes and recovered by centrifugation with a final washing with 20 mM Tris buffer pH 
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7.5 at 4ºC. After the harvesting of E56A mutant cells was complete, cells were flash 
frozen in liquid N2 and stored at -80ºC for future use. 
When needed, these cell samples were then left to thaw on ice with the addition 
of 1mM PMSF and resuspended in 20 mM Tris buffer pH 7.5 with 10% glycerol. The 
cells were then lysed by sonication using 30 pulses of 10 second duration with 
intermittent cooling on ice (approximately 1 minute). The resulting solutions were then 
placed in a JA 25.50 rotor and spun at 20 000 rpm for 15 minutes at 4˚C. 
 
A!IO! EXCHA!GE CHROMATOGRAPHY 
 
Lysates obtained were diluted to 40 mLs and applied (in 4 X 10 mL injections) 
to a 1 mL Bio-Scale ™ Mini UNOsphere ™Q Cartidge obtained from BIORAD. The 
column was first equilibrated with 20 mM Tris pH 7.5 and 10% glycerol. The protein was 
then eluted using a linear gradient of KCl to a final concentration of 1M over a 100 
minute period using a flow rate of 0.5 mL/ min. 
PRECIPITATIO! A!D SIZE EXCLUSIO! SEPARATIO! 
 
The fractions that contained a band as determined by SDS-PAGE analysis was 
consistent with GlxI protein of around 14 kDa were pooled. This sample was then 
dialysed overnight against a solution of 10% glycerol and water with the addition of 
1mM PMSF. After dialysis, the sample was subjected to centrifugation using a JA 25.5 
rotor at 10,000 rpm at 4ºC for 30 minutes. Half of the protein samples obtained were then 
concentrated. This solution was then spun through a 30 kDa cut off membrane and the 
flow through collected. This solution was then concentrated and stored in 50 mM MOPS 
pH 7.   
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PREPARATIO! OF METAL FREE PROTEI! 
 
The second half of the supernatant obtained after centrifugation was subjected 
to dialysis in 10% glycerol and MilliQ water using SPECTRA/POR® dialysis tubing 
with a molecular weight cut off of 12- 14 kDa. Isoelectric focusing was then performed to 
ascertain metal free protein as was previously described for wild type GlxI. The resultant 
samples that were positive for GlxI expression (as determined by SDS-PAGE) were then 
exchanged into Chelex treated 50mM MOPS in metal free plasticware for later use.  
 
PROTEI! CALIBRATIO! A!D METAL REI!CUBATIO! 
 
Protein concentration was then determined by Bradford analysis as explained 
previously. In addition to this substrate concentration was also determined as explained 
previously.  
The enzyme samples prepared were of the apo enzyme, holo enzyme as well 
apo enzyme reincubated overnight in the presence of the following metals: Ca 2+, Cd2+, 
Cu2+, Co2+, Mg2+, Mn2+, Ni2+, Zn2+. GlxI substrate concentration of 0.5 mM was then 
used to screen for activity for each metal. These assays were done in triplicates in three 
different experiments applying the same conditions for a standard GlxI assay. Product 
formation was then determined at 240 nm for the appearance of the thioester.  
For lysate screening, assay conditions was set up similar to the GlxI standard 






LYSATE ASSAY SAMPLE PREPARATIO!S 
 
Samples prepared for assaying of the lysate were grown first with a starter 
culture and next in a 50 mL culture. This 50 mL sample was grown and induced in the 
same conditions used to harvest the enzyme. The cells were then lysed under the same 
conditions as previously explained except the wash and lysis buffers were composed of 
100 mM KPB pH 7.0 (the same buffer used to determine enzymatic activity) without the 
addition of PMSF or glycerol. Approximately 0.08 and 0.06 g of cells were harvested 
from the wild type and E56A mutant cells respectfully and diluted to 2 mL. Substrate 
concentrations ranging from 0.02 to 1.0 mM were prepared. The enzyme lysate solution 
was then diluted 10-fold then 5 µL added to each 300 µL total assay volume.  
 
MASS SPECTROMETRY A!D CIRCULAR DICHROISM A!ALYSIS 
 
Molecular mass for the protein was determined using electrospray ionization 
mass spectrometry (ESMS) as explained previously. In addition to this, Circular 
Dichroism (CD) analysis was performed to determine possible changes in the secondary 
structure or denaturation of the protein because of the E56A mutated protein. CD detects 
the differential absorbance of left and right circularly polarized light. The three common 
structural motifs that are observed are α helices, β sheets and random coil. These motifs 
exhibit a distinct CD spectra in the far-ultraviolet (UV) region (170-260 nm). In the near-
UV region of the spectra (320-260 nm) a fingerprint of the protein structure can be 
estimated based on the asymmetric environments of the aromatic amino acids that are 
sensitive to protein conformation. CD data is reported in units of molar ellipticity ([θ], 
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deg.cm2/dmol), where the conversion from molar extinction uses the following 
relationship: [θ] = 3298 ∆ε (227-229).  
E56A mutant protein was diluted to an approximate concentration of 15.8 nM in 
50 mM MOPS pH 7.0. The data for CD analysis was collected from 300-190 nm with a 
resolution of 0.2 nm. Sensitivity was monitored in mdeg with a bandwith and response 
time of 1 nm and 0.125 sec respectively at a speed of 50 nm/min. The data was 





Recovered sequence analysis confirmed the E56A mutation, with all other 
residues of the protein coinciding with the sequence of the wild type. This can be seen in 
the following diagram which displays the protein sequence of the wild type enzyme as 
well as the amino acid counterparts. The sequence of the E56A mutant enzyme is also 
















      M   R   L   L   H   T   M   L   R   V   G   D   L   Q   R   S   I   D   F   Y       
WT    ATG CGT CTT CTT CAT ACC ATG CTG CGC GTT GGC GAT TTG CAA CGC TCC ATC GAT TTT TAT  60 
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||     
E56A  ATG CGT CTT CTT CAT ACC ATG CTG CGC GTT GGC GAT TTG CAA CGC TCC ATC GAT TTT TAT  60 
 
      T   K   V   L   G   M   K   L   L   R   T   S   E   N   P   E   Y   K   Y   S       
WT    ACC AAA GTG CTG GGC ATG AAA CTG CTG CGT ACC AGC GAA AAC CCG GAA TAC AAA TAC TCA 120 
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||     
E56A  ACC AAA GTG CTG GGC ATG AAA CTG CTG CGT ACC AGC GAA AAC CCG GAA TAC AAA TAC TCA 120 
 
      L   A   F   V   G   Y   G   P   E   T   E   E   A   V   I   E   L   T   Y   N       
WT    CTG GCG TTT GTT GGC TAC GGC CCG GAA ACC GAA GAA GCG GTG ATT GAA CTG ACC TAC AAC 180 
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |   ||| ||| ||| ||| 
E56A  CTG GCG TTT GTT GGC TAC GGC CCG GAA ACC GAA GAA GCG GTG ATT GCC CTG ACC TAC AAC 180 
 
      W   G   V   D   K   Y   E   L   G   T   A   Y   G   H   I   A   L   S   V   D       
WT    TGG GGC GTG GAT AAA TAC GAA CTC GGC ACT GCT TAT GGT CAC ATC GCG CTT AGC GTA GAT 240 
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| 
E56A  TGG GGC GTG GAT AAA TAC GAA CTC GGC ACT GCT TAT GGT CAC ATC GCG CTT AGC GTA GAT 240 
 
      N   A   A   E   A   C   E   K   I   R   Q   N   G   G   N   V   T   R   E   A       
WT    AAC GCC GCT GAA GCG TGC GAA AAA ATC CGT CAA AAC GGG GGT AAC GTG ACC CGT GAA GCG 300 
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||     
E56A  AAC GCC GCT GAA GCG TGC GAA AAA ATC CGT CAA AAC GGG GGT AAC GTG ACC CGT GAA GCG 300 
 
      G   P   V   K   G   G   T   T   V   I   A   F   V   E   D   P   D   G   Y   K       
WT    GGT CCG GTA AAA GGC GGT ACT ACG GTT ATC GCG TTT GTG GAA GAT CCG GAC GGT TAC AAA 360 
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||     
E56A  GGT CCG GTA AAA GGC GGT ACT ACG GTT ATC GCG TTT GTG GAA GAT CCG GAC GGT TAC AAA 360 
 
      I   E   L   I   E   E   K   D   A   G   R   G   L   G   N   STOP    
WT    ATT GAG TTA ATC GAA GAG AAA GAC GCC GGT CGC GGT CTG GGC AAC TAA 408 
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||     
E56A  ATT GAG TTA ATC GAA GAG AAA GAC GCC GGT CGC GGT CTG GGC AAC TAA 408 
 
Figure 39. Sequence comparison of the wild type E. coli GlxI with the E56A sequence to verify 
mutation 
 
A!TIBACTERIAL RESISTA!CE GROWTH STUDIES 
 
RESISTA!CE TO MG 
 
Growth studies on cells containing the GlxI enzymes showed an increase in 
susceptibility of the mutant bacteria to MG. Cells with wild type GlxI were able to 
proliferate more at higher concentrations of MG. At very low concentrations of MG there 
seemed to be no significant change in the WT and E56A cell growth patterns. Wild type 
cells were resistance to up to 6.4 mM MG present in the broth solution. Interestingly, the 
E56A mutation slowed growth in cells of 3.2 and 6.4 mM MG. These cells exhibited 

























Figure 40. Growth curve displaying MG resistance in vivo for WT GlxI 



















Figure 41. Growth curve displaying MG resistance in vivo for E56AGlxI 
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RESISTA!CE TO FOSFOMYCI! 
 
GlxI E56A mutant cells showed significant differences in increased tubidity 
when compared to the wild type enzymes. GlxI containing cells from E. coli did not 
display fosfomycin resistance and the data coincided with previously tested growth 
experiments in the literature indicating that the MIC for fosfomycin with this E. coli 
strain is less than 0.0964 mM (207). Here the cells that were grown overnight with 
antibiotic concentrations of 0.08 mM and lower displayed turbidity. Cells containing the 
E56A mutation showed growth patterns at higher concentrations of the antibiotic, very 
similar to those of the wild type GlxI containing cells which were not treated with the 
antibiotic. In addition to this, overnight cultures exhibited cell growth when the medium 



























Figure 42. Growth curve displaying the action of fosfomycin on WT GlxI in vivo 
 



















Figure 43. Growth curve displaying the action of fosfomycin on E54A GlxI in vivo 
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PROTEI! EXPRESSIO! A!D PURIFICATIO!  
 
Successful expression of the E56A mutant protein was achieved in 
MG1655/pGL10 competent cells. The condition with optimal protein recovery was with 
0.7 OD growth at 37ºC inducing for eight hours with 0.7 mM IPTG. During purification 
the expression and harvesting of the competent cells was monitored using SDS-PAGE. 
The protein that coincided with the molecular weight of wild type GlxI E. coli was 
obtained between 220 - 320 mM KCl after the lysate sample was applied to the 
UNOsphere column. 
The E56A mutant protein sample was successfully purified in both apo and holo 
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METAL SCREE!I!G ACTIVITY ASSAYS 
 
Metal screening assays conducted showed a significant loss in activity of all the 
metals tested in reference to GlxI activity when compared to the specific activity obtained 
previously of 704 ± 0.4 µmol/min/mg on page II-97. The greatest loss in activity occurred 
when the enzyme was reconstituted with Zn2+.  

































Figure 46. Activity obtained from E56A under various enzymatic conditions. Holo indicates enzyme 
purified from the column and apo represents the enzyme sample after it has been processed by 
isoelectric focusing.  
 
CELL LYSATE A!ALYSIS  
 
Since activity was not detected in the holo nor under conditions in the presence 
of various metals, lysate assays were conducted to see whether or not the purification 
process rendered the enzyme inactive. The expression levels of the protein differ in the 
wild type and the E56A mutant enzyme with the former being more robust and according 































































ASSAY FOR GLXIACTIVITY 
 
A typical GlxI activity assay was conducted on the E56A mutant. Data collected 
displayed a significant decrease in activity for the hemithioacetal when compared to wild 




Scientists discuss the ever increasing problem of antibiotic resistance in 
pathogenic microorganisms (220). Resistance in these organisms is thought to be as a 
result of selective pressure on microbial populations that occur when the antibiotic is 
used. Mechanisms for these kinds of alterations have all been observed in relation to the 
Fos proteins (205, 220). 
Fosfomycin is a broad spectrum antibiotic that was once effective against Gram 
positive and Gram negative bacteria (208, 209). Originally synthesized and characterized 
by Merck, this antibiotic was able to block bacterial cell wall biosynthesis by inhibiting 
the enzyme MurA. MurA is a very important bacterial enzyme as it catalyses the 
committed step in this process (208-211). Since the introduction of this antibiotic, the 
bacteria has presented magnificent ways to proliferate by introducing mutations on the 
MurA enzyme and most profoundly introducing a new class of enzymes coined the 
fosfomycin resistance proteins. This class consists of Fos A, Fos B and Fos X, all 
catalyzing different reactions in order to render the antibiotic useless in the cell (205, 
220).  
The enzymes are thought to have developed over the years through gene 
mutation events making FosA the most catalytically efficient enzyme (197). If this is true 
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the structure of the protein has also developed from its proposed enzymatic precursors. In 
addition to this, the enzyme belongs to the VOC superfamily of proteins coined mainly 
for its mechanistic properties but also is comprised of mostly metalloenzymes and a 
characteristic βαβββ structural motif (53). 
Observing the superfamily allows one to postulate structurally related 
development of the mechanisms as with a few changes in the amino acid sequences 
among the protein they have become mechanistically diverse (53). GlxI is also member 
of this superfamily and draws significant similarity in the active site Mn2+ metal 
coordination to Fos A (53, 64, 217). By making a single mutation (E56A), the newly 
introduced alanine residue opens the active site allowing the protein to possibly switch 
metal specificity and more remarkably switch functionality.  
Cell growth conditions indicated that the mutant enzymes did not proliferate as 
well as the wild type bacteria under normal growth conditions and thus expression 
optimization had to be conducted. When determining the E56A cell performances in the 
presence of MG, these E56A mutant bacteria took longer to grow and were inhibited with 
a 10 fold difference from the wild type enzyme. This not only confirms that the main 
source of degradation of MG is the glyoxalase system but that this mutation significantly 
affects the enzyme’s response to its natural substrate. However, any growth could be 
attributed to other enzymes in the system that could conduct glyoxalase activity such as 
GlxIII and other routes of MG degradation that have been previously discussed.  
The antibiotic resistance studies concerning the effect of fosfomycin in vivo, 
indicate preliminarily that the mutation caused the bacteria to acquire resistance to the 
antibiotic. These results are very promising but still inconclusive and kinetic analysis of 
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the purified enzyme could reveal fosfomycin degradation activity. If this is the case then 
it would confirm scientific postulations on the evolution of enzymes characterised in a 
superfamily. One could make a further assumption that when kinetics are obtained on this 
enzyme it could be more similar to the kinetics of the FosX enzyme as it contains only 
one metal binding site while FosA has developed two metal binding site to make the 
catalysis more effective.  
The E56A mutation in GlxI produced an inactive GlxI enzyme. One prossibility 
is that even though the enzyme was metallated in MOPS buffer, when placed in 100 mM 
phosphate buffer the affinity for the metal to the phosphate buffer could have been 
stronger than the enzyme’s affinity for the metal. This mutation at the active site could 
have weakened the metal binding of Ni2+. However it is still possible that the enzyme is 
binding the metal due to inactivation caused in the presence of Zn2+. Future assays could 
be conducted in a sulphonic buffer such as MES or MOPS since these buffers do not 
effectively compete for metals.  
Also if the enzyme is binding the metal, supplementing the growth media with 
the metal such as Ni2+ or Mn2+ might increase the affinity for the metal. This was shown 
in the wild type GlxI enzyme. When the growth media was supplemented with Ni2+, a 
more active enzyme was achieved (60).  
FUTURE WORK 
 
Metal analysis data will be obtained on the E56A mutant enzyme which will 
allow the identification of the native metal in the active site . In addition to this, kinetic 
data will be obtained for E56A using the standard kinetic assays for FosA. However, if 
this reaction is not successful and there is no FosA activity, then activity assays should be 
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conducted under conditions used the determination of FosX (205) and FosB (207) 
activity. 
Structural analysis via NMR or X-ray Crystallography could be conducted in 
order to determine the precise structure of the active site and as a result give indications 
















Since the 1940s scientists have probed the area of genetics seeking to 
understand the biosynthetic pathways for enzyme building blocks such as amino acids 
and coenzymes (230). Since enzyme production is therefore genetically controlled (231, 
232) further research probing the structural characteristics of enzymes revealed that these 
structures are also genetically determined (233). Scientists therefore embarked on ways 
of using this information to produce mutant proteins by altering the genetic sequence 
(234). 
Upon analysis of the genes of various organisms, sequence similarities were 
observed by Ingram in 1961 among genes which raised the question of whether these 
genes evolved from a common ancestral polypeptide (232). In his research, he suggested 
that there seemed to be duplication of the original α-polypeptide gene in human 
hemoglobins. He also suggested that there could be subsequent convergence of the 
duplicates whether by mutations or other means to form the β and δ genes. These genes 
correspond to their respective polypeptide chains designated :α, β, δ, and the γ 
hemoglobin chain which at the time was not analysed (235, 236). Ingram’s work strongly 
indicated that these proteins may have evolved from various mutational events; therefore, 







GLXI E!ZYME EVOLUTIO! 
 
The main means of enzyme alteration among the GlxI enzymes is thought to 
have occurred by gene duplication (53). This process occurs by a variety of mutational 
mechanisms such as polyploidy which was the first observed and is described as the 
doubling of the entire chromosome compliment. Aneuploidy could also occur where 
there is a complete loss or gain of particular chromosomes. Chromosomal parts may also 
be lost or duplicated. In addition to this, external stressors or environmental conditions 
can even cause small scale mutations and give rise to isoenzymes, and new gene 
sequences (237).  
 For the evolution of GlxI and related proteins that contain the βαβββ topology, 
several authors have proposed that an ancestoral gene for the βαβββ protein fold module 
existed which was possibly monomeric in nature (238). Over time, gene duplication, gene 
fusion as wells as point mutations could have given rise to a gene that coded for a two 
model or dimeric enzyme. It was previously discussed that the enzymes of the βαβββ 
superfamily have a similar structural fold but catalyze a diverse set of reactions. Members 
which were most similar in their active site mechanisms could have developed from gene 
duplication and mutation but not gene fusion. Further evolutionary development could 
have been undertaken on the sequences for GlxI enzymes and the DIOX (238) lineage 
which are thought to have undergone a gene duplication and fusion event which gave rise 
to the ancestor of the four-module monomers. Specifically in the GLO lineage, into 
which GlxI belongs, independent duplication and fusion events could have given rise to 





Figure 49. Postulated evolutionary scheme that lead to genes encoding for known protein  homologs 
such as BRP, DHBD, and GLO. Each of the rectangles represent the βαβββ motif. The purple filled 
rectangle represents the possible monomeric ancestor, while the red and blue representations are of 
even and odd modules respectfully. In the third line the boxes grouped together represent proteins 
that have similar functions and evolve into modern protein examples which are members of the 
βαβββ superfamily (53). 
 
EVOLUTIO! OF THE METAL BI!DI!G ACTIVE SITES 
 
Among the members of the βαβββ superfamily, it is reasonable to state that 
even though the substrates differ and some mechanisms and active site ligands vary, there 
is some similarity with the location of the active site and the metal site coordination in 
these protein environments. One of the most striking comparisons is with DHBD and 
GlxI where the metal and ligand coordination in the active site very similar even though 















Gene duplication and fusion 





In all of these proteins the metal ligands are always in pairs which are located 
between the β1 and the β4 secondary structures in edge to edge contact and related by a 
pseudo two-fold symmetry. These ligand locations imply that there was likely a 
formation of a symmetric oligomeric protein that could bind metal with four ligands 
occurred in the evolutionary process (53). One member, BRP, challenges these theories 
as it lacks a metal binding site and the protein does not conduct a reaction mechanism 
similar to the other members rather it just binds the molecule bleomycin (198). When 
analyzing the sequence of BRP with other members of the βαβββ superfamily, there is 
evidence that there could exist within the BRP sequence positions for metal binding even 
though metal binding does not occur in BRPs. Further analysis of the family would 
indicate that a loss of a metal ligand could have resulted in the emergence of different 
mechanisms entirely as is thought to be the case for the DIOX enzymes (53, 238, 239). 
Y. pestis       MR-------- ---------- ---------- --LLHTMLRVG DLQRSIDF 19 
E. coli         MR-------- ---------- ---------- --LLHTMLRVG DLQRSIDF 19 
N. meningitidis MR-------- ---------- ---------- --LLHTMLRVG NLEKSLDF 19 
P. putida       MS-------- LNDLNTLPGV TAQADPATAQ FVFNHTMLRVK DIEKSLDF 41 
H. sapiens      MAEPQPPSGG LTDEAAL-SC CSDADPSTKD FLLQQTMLRVK DPKKSLDF 48 
 
 
Y. pestis       YTKVLGMRLL RTSENTEYKY SLAFVGYSDE SK--------- ------GSVI 55 
E. coli         YTKVLGMKLL RTSENPEYKY SLAFVGYGPE TE--------- ------EAVI 55 
N. meningitidis YQNVLGMKLL RRKDYPEGRF TLAFVGYGDE TD--------- ------STVL 55 
P. putida       YTRVLGFKLV DKRDFVEAKF SLYFLALVDP ATIPADDDARH QWMKSIPGVL 92 
H. sapiens      YTRVLGMTLI QKCDFPIMKF SLYFLAYEDK NDIPKEKDEKI AWALSRKATL 99 
 
 
Y. pestis       ELTYNWGVDQ -----YDMGT A----FGHLA LGVDDVAATC DQIRQAGGKV 105 
E. coli         ELTYNWGVDK -----YELGT A----YGHIA LSVDNAAEAC EKIRQNGGNV 105 
N. meningitidis ELTHNWDTER -----YDLGN A----YGHIA VEVDDAYEAC ERVKRQGGNV 105 
P. putida       ELTHNHGTER DADFAYHHGN TDPRGFGHIC VSVPDVVAAC ERFEALQVPF 142 
H. sapiens      ELTHNWGTED DETQSYHNGN SDPRGFGHIG IAVPDVYSAC KRFEELGVKF 149 
 
 
Y. pestis       TREA--GPVK GGNTIIAFVE DPDGYKIELI ENKSAGDCLG N--- 135 
E. coli         TREA--GPVK GGTTVIAFVE DPDGYKIELI EEKDAGRGLG N--- 135 
N. meningitidis VREA--GPMK HGTTVIAFVE DPDGYKIEFI QKKSGDDSVA YQTA 138 
P. putida       QKRLSDGRMN H----LAFIK DPDGYWVEVI QP----TPL- ---- 173 
H. sapiens      VKKPDDGKMK G----LAFIQ DPDGYWIEIL NPNKMATLM- ---- 184 
Figure 50. Amino acid sequence alignment the GlxI enzymes of Y. pestis (accession number 
EDM42195), E. coli (accession number BAE76494), . meningitidis (accession number CAM09244), 
P. putida (accession number AAA61758), and H. sapiens (accession number (AAB49495) 
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METAL CLASSES OF GLXI E!ZYMES 
 
It was first demonstrated by Davis and Williams in 1966 that GlxI from calf 
liver was inactivated after being introduced into a solution containing 2 mM EDTA 
(ethylenediaminetetraacetic acid) (240). Upon introducing varying divalent metals into 
the apoenzyme, the activity of the GlxI enzyme has also been found to vary. Since then, 
other mammalian GlxI enzymes have been identified and characterised displaying the 
presence of metal in their active sites (241-244). Analysis of GlxI enzymes from yeast 
and human sources have revealed the presence of Zn2+ in their active sites (245). 
Reconstitution assays were conducted on the human enzyme which revealed a 
comparatively smaller dissociation constant for Zn2+ relative to other metals (246). Thus 
to that point, only Zn2+ binding was discovered for eukaryotic GlxI enzymes; however, 
analysis of the GlxI enzyme from Pseudomonas putida revealed that it is also activated 
by Zn2+ even though it can be activated by a wide range of metals with varying activation 
levels (200, 245). 
 
PROPERTIES OF ZI!C I! ORGA!ISMS 
 
Zn2+ is the most common bivalent metal found in a variety of metalloenzymes 
(247). Of its many properties, Zn2+ is able to alter its metal coordination and geometry 
during catlaysis. In GlxI metal centers for example it is able to exist in tetracoordinate, 
pentacoordinate and hexacoordinate forms and this property of the enzyme to fluctuate in 
its coordination can be critical for proper activity(247). In addition to this, rapid exchange 
of water molecules that can act as active site ligands are common with Zn2+ 
metalloproteins (248). Zn2+ is also most stable in its divalent form in aqueous media (249, 
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250). It is able at physiological pH to remain stable in metal hydrate and hydroxide forms 
encouraging the capacity for general base and acid catalysis by water ligands in the active 
site (250). Zn2+ does not readily undergo oxidation or reduction reactions as other metals 
such as Mn2+ and Co 2+ do. This non redox role is epitomized in GlxI enzyme catalysis 
and there is a remarkable metal ion affinity for Zn2+ as compared to other metal ions such 
as Ca2+, Mg 2+ (251). 
 
THE PRESE!CE OF !O!-ZI!C METALLOE!ZYMES 
 
More recently, scientists have discovered the existence of enzymes that are not 
most active in the presence of Zn 2+. Metal analysis of such enzymes have led to the 
revelation that some of these enzymes are complexed in the native state with Ni2+ such as 
in GlxI from E. coli and that they can be activated also by Co2+ (249, 252-254). Ni 2+ 
biochemistry has been associated with both redox active, as in the enzyme methyl-CoM-
reductase (MCoMR), as well as non redox inactive enzymes such as urease (254, 255). 
GlxI from E. coli was the first report of a Ni2+ activated GlxI enzyme (61).  
This classification was pioneered by Sukdeo and coworkers who performed 
biochemical characterization as well as metal reactivation studies on GlxI from the 
organisms: E. coli,  P. aeruginosa, Y. pestis and 3. meningitides (62). All of the 
organisms studied displayed maximal activation in the presence of Ni 2+ ion while Zn2+ 
activity was not detected or has significantly reduced as in the case of GlxI from 3. 
meningitidis (62).  
Activity profiles and metal titration studies were conducted showing similar 
activation characteristics among the GlxI enzymes, with GlxI from 3. meningitidis 
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having the lowest specific activity. Catalytic efficiencies among all the enzymes, 
however remain comparable whether the enzyme is activated by Ni2+ or Co2+ (62). 















E. coli Ni2+ 27±0.4 676±17 338 12 
 Co2+ 12±2 213±33 106 8.8 
Y. pestis Ni2+ 56±0.6 618±48 306 5.5 
 Co2+ 29±5 140±6 69 2.4 
P. aeruginosa Ni2+ 32±2 571±28 271 8.5 
 Co2+ 16±3 180±7 86 5.4 
3. meningitidis Ni2+ 45±5 390±5 204 4.5 
 Co2+ 28±0.5 279±24 146 5.2 
 






Specifically targeting the metal reactivation geometry of the active site in E. 
coli, studies with the Ni2+ and Zn2+ forms have shown that the active site geometry is 
octahedral in the Ni2+ form and has a trigonal bipryamidal arrangement in the Zn 2+ 
bound form (256, 257). The x-ray structure of the E. coli GlxI enzyme complexed with 
Zn2+, Ni2+, Co2+ and Cd2+ as well as the metal free apo form have been obtained and 
analyzed (64). No major structural changes have been observed among these enzyme 
samples other than that the inactive Zn2+ form has a trigonal bipyrimidal structure (61, 
249). These studies do confirm that E. coli GlxI is active with metals that form an 
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octahedral geometry which is contributed by four metal protein ligands and two water 
molecules, rather than a five coordinate system found in the Zn2+ enzyme which differs 
by containing only one water molecule (64). Even though x-ray structural studies on the 
enzyme with Mn2+ were unsuccessful, analysis of the electron spin resonance of this 
Mn2+ form indicates the existence of an octahedral environment for this activating metal 
(64). 
  
                                (A)                                                                    (B) 
Figure 51. Coordination of the E. coli active site in the presence of (A) !i
2+
 and (B) Zn
2+
displaying 
the active site water molecules (64) 
 
GLXI FROM PSEUDOMOAS AERUGIOSA 
 
Work done by Sukdeo and coworkers have established the existence of two 
classes of metal activation in GlxI (62). A year ago, Sukdeo and Honek reported the 
existence of three GlxI enzymes in P. aeruginosa after analysis of the PAO1 genome of 
this bacteria (258, 259). These enzymes originated from the locus coined gloA1, gloA2 
and gloA3. Previous kinetic characterisation (coinciding with the data presented in table 
11) was from the gene product of gloA1. This enzyme was associated with Ni 2+ 
activation. The other two isoenzymes have now been characterised (260), and it is 
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surprising to find that this organism contains both Ni2+ and Zn 2+ activated enzymes that 
are transcription products of gloA2 and gloA3 respectively (260). Furthermore, sequence 
comparison of the proteins with the human enzyme (GLO) indicate some significant 
sequence similarities to the GloA3 of P. aeruginosa which are not present in the E. coli 
enzyme (260) and many of the other GlxI enzymes that were studied a few years earlier 
(62).  
Analyzing the sequence of the GlxI enzymes that were Ni2+ activated, 
significant conservation of all the metal binding residues were detected. However, when 
compared to the eukaryotic counterpart the very first metal binding residues differs from 
a histidine to a glutamine (shown in yellow in figure 50). This was a promising target for 
site directed mutagenesis to determine if a change in metal specificity could occur by 
creating a H5Q mutation in the E. coli wild type GlxI enzyme. However, the existence of 
a Zn2+ activated enzyme from P. putida (which has a histidine at this position), indicates 
that metal activation could not be solely due to what amino acid is at the position shared 
by its prokaryotic counterparts as is shown in figure 48.  
It seems that the metal specificity of these enzymes is much more complex than 
altering an active site residue. Sequence analysis in figure 49 shows conserved sequences 
possessed by the enzyme from P. putida that are very similar to the human enzyme. More 
remarkably, these sequences are also very similar to those of GloA3 from P. aeruginosa 







                   (A) 
E. coli    MR--------------------------------LLHTMLRVGDLQRSID 18 
GloA1      MR--------------------------------ILHTMIRVGNIDRSID 18 
GloA2      MR--------------------------------ILHSMLRVADLEAALE 18 
GloA3      MSFNTEVQP---GI--------CMEPDAITQEYVFNHTMLRVKDPKRSLD 39 
P. putida  MSLNDLNTLP---GVT-------AQADPATAQFVFNHTMLRVKDIEKSLD 40 
H. sapiens MA---EPQPPSGGLTDEAALSCCSDADPSTKDFLLQQTMLRVKDPKKSLD 47 
                                               *                 
 
                                                  (B) 
E. coli    FYTKVLGMKLLRTSENPEYKYSLAFVGYGPETE---------------EA 53 
GloA1      FYTRVLGMTLLRKNDYPDGQFTLAFVGYGNEAD---------------SA 53 
GloA2      FYTRALDMRLLRRRDYPEGRFTLAFVGYQDERA---------------AA 53 
GloA3      FYSRVLGMRLLRRLDFEEGRFSLYFLAMTRGEEVPDAVDERQRYTFGRQS 89 
P. putida  FYTRVLGFKLVDKRDFVEAKFSLYFLALVDPATIPADDDARHQWMKSIPG 90 
H. sapiens FYTRVLGMTLIQKCDFPIMKFSLYFLAYEDKNDIPKEKDEKIAWALSRKA 97 
 
 
                        (C)      (D) 
E. coli    VIELTYNWGVDK-----YELGT----AYGHIALSVDNAAEACEKIRQNGG  94 
GloA1      VIELTHNWGVDA-----YEIGT----GYGHIAIEVDDAYQACDDIRYNGG  94 
GloA2      ALELTHNWDRDG-----YTQGD----GYGHLAIEVEDAAVTCARARALGY  94 
GloA3      VLELTHNWGSESDDSQ-YHNGNQDPRGFGHICFSVPDLVAACERFETLGV 138 
P. putida  VLELTHNHGTERDADFAYHHGNTDPRGFGHICVSVPDVVAACERFEALQV 140 
H. sapiens TLELTHNWGTEDDETQSYHNGNSDPRGFGHIGIAVPDVYSACKRFEELGV 147 
             *                          * 
 
              (E)       (F) 
E. coli    NVTR--EAGPVKGGTTVIAFVEDPDGYKIELIEEKDAGRGLGN 135 
GloA1      QVTR--EAGPMKHGTTVIAFVTDPDGYKIELIQKS-------S 128 
GloA2      RVTR--EAGLMQHGRSVIAFLEDPDGYKVELIQKGTQF----D 131 
GloA3      NFVKPLDRG-MKN----VAFISDPDGYWVEIVQASLNGEMGRG 176 
P. putida  PFQKRLSDGRMNH----LAFIKDPDGYWVEVIQPTPL------ 173 
H. sapiens KFVKKPDDGKMKG----LAFIQDPDGYWIEILNPNKMATLM-- 184 
                                        * 
Figure 52. Sequence alignments of E. coli GlxI (accession number BAE76494), GlxI enzymes found in 
P. aeruginosa: GloA1 (accession number AAG06912), GloA2 (accession number AAG04099), GloA3 
(accession number AAG8496) . P. putida ( accession number AAA61758), and H. sapiens (accession 
number (AAB49495) Active site metal ligands are bolded. 
These findings indicate that the positions in figure 3 designated A -E could have 
significant effects on metal binding on the GlxI enzyme as these residues are not located 
in the E. coli enzyme. This hypothesis is even more feasible as these sites are also 
missing in the GloA1 and GloA2 strains from the same organism, making this a 




STUDIES O! THE GLOA E!ZYMES 
 
Initial studies on the GloA enzymes confirmed that GloA1 and GloA2 are 
maximally active in the presence of Ni2+. The assays were also conducted in the presence 
of Co2+ with the catalytic efficiencies being comparable. In addition to this the kinetic 
efficiency of GloA3 is also comparable to the other two enzymes even though the kcat of 
the GloA3 enzyme is much higher than those of the other GlxI isoenzymes. The catalytic 
efficiencies of the human enzyme is more comparable to the enzyme GloA2 in the 
presence of Ni2+, however, the specific activities of the human and GloA3 enzymes are 
much more similar than to those of the other enzymes 
Table 11. Kinetic Parameters for the Zn
2+
- vs non Zn
2+














GLO (human) Zn2+ 66±5 2340±1 1500 23 
GloA3 Zn2+ 287±47 1176±4 787 2.8 
GlxI (E. coli) Ni2+ 27±0.4 676±17 338 12 
 Co2+ 12±2 213±33 106 8.8 
GloA1 Ni2+ 32±2 571±28 271 8.5 
 Co2+ 16±3 180±7 86 5.4 
GloA2 Ni2+ 21±0 497±8 37 12 
 Co2+ 24±11 75±1 247 1.6 
 
There are also a few more commonalities based on sequence comparisons of the 
enzymes. Region A in figure 50 was associated with an 3-terminal arm-like structure 
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which wraps around the complimenting subunit of the protein (displayed in figure 51). 
This is the longest structure among the GlxI enzymes from P. putida and the human 
enzyme that is most similar to the GloA3 enzyme. To continue regions B, C and D are 
also large sequence gaps that are similar to the Zn2+-utilizing enzymes that are not present 
in any of the Ni2+-utilizing enzymes. Sukdeo and colleagues performed a deletion of 
region A from the structure of the protein. The resultant protein formed aggregates in 
solution and lysate assays of the enzyme, exhibited no activity could be detected (260).  
 
Figure 53. A theoretical model of the GloA3 monomer from P. aeruginosa, boxed sections coincide 
with sequences that are missing in GlxI E. coli, but code for similar regions of GLO (261-263).  
 
IMPORTA!CE OF STUDYI!G P. AERUGIOSA 
 
P. aeruginosa is a biologically versatile aerobic Gram-negative rod bacterium 







insects (264). This bacteria is biochemically versatile and environments where the 
bacteria proliferate are associated with wet marshy areas. It is also present in the hospitals 
where it will live on respirators, humidifiers and sinks (264).  
P. aeruginosa is therefore a prime source of infection for immuno-compromised 
patients such as cancer and burn victims, but those most affected are people living with 
cystic fibrosis (CF). This disease is fatal and one of the most common in North America 
particularly in the United States which affects over 30, 000 individuals. It is most 
prevalent among caucasions and occurs one in every 3300 livebirths (265). Among the 
bacteria found in patients with this disorder, P. aeruginosa accounts for approximately 
90% of the bacterial population in victim sputums examined and is usually found in lung 
tissue or more specifically respiratory epithelial cells (265) and adheres to lung tissue 
more than other bacteria (265). 
 
MATERIALS A!D METHODS 
 
This research is based on studying the metal selectivity of GloA3 after several 
mutations of the sequences corresponding to regions B, C and D as shown in figure 50. In 
order to perform this study, primers must be designed for these deletions and sequency 
analysis done in order to confirm the mutations. The proteins will then be expressed, and 
purified. These purified proteins will then be subjected to GlxI activity assays to 
determine the effects of the mutations on the activity of the native mutant proteins as well 
as reconstitution assays. The native purified proteins will be sent for metal and CD 





Figure 54. Sequence of events for the analysis of GloA3 generated deletions 
DELETIO!S  
 
Site mutations were performed on regions B-D. The mutations were identified 
using the following nomenclature.  
Table 12. !omenclature of regional deletions 









Deletions on these regions were performed using QuickChange® site directed 
mutagenesis. This procedure was performed on the template wild type P. aeruginosa 
DNA coding for GloA3 obtained from E. coli DH5α competent cells. The template for 
Primer Design Generate Deletions Sequence Analysis 




Metal Analysis Enzyme Assay CD Analysis 
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wild type P. aeruginosa strain PA01 was obtained from Dr. J. Lam of the University of 
Guelph (Ontario, Canada). 
PRIMER DESIG! A!D PCR CO!DITIO!S 
 
Primers were designed according to the QuickChange® protocol and are listed 
as follows for the forward and reverse directions for the designated deletions. For 
multiple deletion sites, after the desired mutation was achieved from the first step then 
the second set of primers were used to make a deletion on that template DNA. To clarify, 
to obtain the deletion bcgloA3, the primers designed to obtain cgloA3 were used on the 
DNA template of bgloA3 instead of the wild type template. The sequence for multiple 
deletions are explained in table 13. 
Table 13. Designed primers for the GloA deletions  


















Table 14. Deletions of multiple sites on the gloA gene 
Deletion sites Primers applied in sequence 
bcgloA3 1. bgloA3 
 2. cgloA3 
bdgloA3 1. dgloA3 
 2. bgloA3 
cdgloA3 1. dgloA3 
 2. cgloA3 
bcdgloA3 1. dgloA3 
 2. cgloA3 
 3. bgloA3 
The PCR conditions for amplification of the DNA were performed under the following 
conditions. 
Table 15. PCR Conditions for D!A Mutant Amplification of the gloA gene  
Segment Cycles Temperature (ºC) Time (s) 
1 1 95 30 
2 30 95 30 
  55 30 
  72 60 
3  72 600 
 
D!A A!D PROTEI! EXPRESSIO! 
 
The DNA obtained was transformed for expression and then sent for sequence 
analysis. The desired deletion products were then transformed into BL21 competent cells 
for protein expression and these groups of cells were optimized in Terrific Broth (TB). 
All these processes were performed using the same conditions as previously explained for 










The BL21 cells containing recombinant plasmids were harvested and 
resuspended in 50 mM potassium phosphate buffer pH 8.0 and then subjected to lysis 
under the same conditions as the GlxI wild type enzyme as described in chapter 2. 
However, 10 mM final concentration of dithiothreitol (DTT) was added in all buffer 
conditions to attenuate methionine oxidation was added as well as 10% glycerol.  
AMMO!IUM SULPHATE PROTEI! PRECIPITATIO!  
 
After lysis the cell debris was removed by centrifugation separated using a JA 
25.5 rotor for 15 minutes at 20000 rpm. The supernatant was then subjected to (NH4)2SO4 
precipitation by the addition of solid (NH4)2SO4 to a final concentration of 1.7 M added 
over the period of 1 hr while spinning on ice and then left spinning for 3 hrs in 50 mM 
KPB. This solution was then respun under the same conditions that were just stated. 
 
PURIFICATIO! BY COLUM! CHROMATOGRAPHY 
 
The supernatant was then filtered and applied to a 1 mL Phenyl HP High Sub 
column obtained from Amersham Biociences. The desired protein was eluted at 0.5 
mL/min with a decreasing gradient of (NH4)2SO4 (1.7-0 M) over a period of 30 minutes. 
The samples that coincided with GloA3 from previous data (260) were pooled and 
subjected to dialysis in 20 mM Tris pH 8.5 at 5ºC overnight. The resulting protein 
solution was then loaded onto a 1 mL Bio-Scale ™ Mini UNOsphere ™Q Cartidge 
obtained from BIORAD. The protein was then eluted with an increasing gradient of KCl 
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(from 0-1M) over a 100 minute period at 0.8 mL/min. The GloA3 protein samples 
obtained were then concentrated to approximately 100 µL and the buffer was exchanged 
to 50 mM Tris pH 8.0. This solution was then applied to a gel filtration column Superdex 
75 (obtained from Amersham) at a flow rate of 0.5 mL/min using one buffer to elute. 
Before application of the protein a gel filtration standard was applied to determine where 
the protein would have been eluted. The putative GloA3 enzymes were then pooled and 
stored in 50 mM MOPS pH 8.0 at 4ºC.  
 
LYSATE ACTIVITY A!ALYSIS 
 
Analysis of the lysates were performed in the same manner as explained 
previously for the E56A mutant of GlxI as discussed in chapter 3.  
RESULTS 
 
SEQUE!CE CO!FIRMATIO!  
 
Amplified DNA obtained by PCR was transformed into DH5α competent E. 
coli cells. The DNA was purified as explained previously and sent for sequence analysis 
as aforementioned for the E56A mutant enzyme in chapter 3. Sequencing results 
indicated that the bgloA3, the cgloA3 and the dgloA3 deletions were all successful. 
These alignments can be seen in the following figures. None of the combination mutation 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The DNA template for the specific construct was expressed to produce protein in 
BL21 competent E. coli cells. The conditions that gave maximum expression were at an 
O.D reading between 0.5-0.7 at 600 nm and with induction with 0.5 to 0.7mM IPTG for 8 
hours. Mutations bgloA3 and cgloA3 required more growth before induction as the 






Cell lysate analysis conducted on the cells containing each protein variant 
indicated that the cgloA3 protein had the lowest activity even though this protein was 
expressed to a greater extent in the cell. The first two mutations displayed activity in the 























































































Figure 56. Lysate profiles displaying activity using GlxI substrate concentrations (0.05-0.07 mM) in a 
final volume of 300 µL. 
CO!CLUSIO! 
 
Enzymes that arise from mutations can perform completely different functions 
or even could have altered the metal specificity of the protein based on just the alteration 
of a few residues. In this study mutagenesis screening on the various proteins were 
performed. Deletion of region (A) in figure 50 produced protein that extensively 
aggregated; this might indicate that this region is necessary for structural purposes to 
keep the protein soluble. All mutations that were achieved in sites (B), (C) and (D) 
individually delivered soluble protein that displayed activity by observation of the cell 
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lysate. The mutation closest to the active site, section (D) does reveal a significant loss in 
activity. Only by obtaining the specific kinetic parameters on the purified proteins can the 
kinetic comparisons be made. 
Purification procedures were successfully optimized to obtain purified protein to 
greater than 80 %. However storage of these proteins exhibited precipitation overnight 
and conditions should be optimized for storage. 
 
CO!TI!UED FUTURE WORK 
 
Purification of all the protein variants should be performed to completion. In 
addition to this, kinetic as well as metal reconstitution assays should be performed in 
order to specify metal affinity and specificity. Also, Position F is also an interesting area 




















EQUIPME!T A!D MACHI!ERY 
 
CELL DISRUPTIO! APPARATUS 
 
The crude cell extracts obtained for purification were obtained after 
resuspension and sonication using a cell Sonicator ™ cell disruptor model W225, 
converter model #2 and a standard tapered microtip, with the output set a 5, from Heat 




When centrifugation required volumes greater than 40 mL the Beckham 
Coulter™ Inc.  Avanti ® J-E Centrifuge (Fullerton, CA) was utilized. In cases when 
protein volumes were less than 5 mLs the Vivaspin 2 Ultrafiltration Centrifugal Device 
was used. Cellulose Triacetate (CTA) membrane was implemented with a molecular 
weight cut off at 10 kDa to concentrate the sample. With larger volumes of proteins such 
as 20 mLs, the Amicon Centricon® concentraters were used. For eppendorf samples that 
needed the use of a centrifugal device, a Biofuge A microcentrifuge (Heraeus Sepatech 




A Pharmacia (now Amersham Biociences, Uppsala, Sweden) fast peptide and 
protein liquid chromatography (FPLC) Biotech system was utilized in protein 





BUFFER A!D CO!TAI!ER PREPARATIO!  
 
All protein related buffers for elution, storage and assaying was made up from 
water filtered with a Millipore 0.22 µm filter (Millipore, Bedford, MA). 
 
PROTEI! CO!CE!TRATIO! A!D BUFFER EXCHA!GE 
 
Obtained purified protein was concentrated and exchanged into storage buffer 
using either Amicon Centricon® YM10 centrifugal concentrators (Millipore, MA) or a 





All spectrophotometric enzymatic assays were conducted using a SpectraMax 
Plus 384 microplate reader from Molecular Devices. This reader also came with the 




All PCR was performed using either a Barnstead/Thermolyne (Dubuque, IA) 
Amplitron II cycler or a Techne® (New Jersey USA) Techgene cycler. 
 




Data was collected between 190 and 300 nm with a Jasco J-715 
spectropolarimeter in a 0.1 cm quartz cell with a band with of 1.0 nm, rate of 20 nm/min 
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